var title_f0_31_496="Hemangioma PI";
var content_f0_31_496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F87009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F87009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemangioma on lip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an example of a hemangioma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Denise W Metry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_496=[""].join("\n");
var outline_f0_31_496=null;
var title_f0_31_497="Brooke end ileostomy";
var content_f0_31_497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    End ileostomy (Brooke ileostomy)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Absorbable sutures are placed full thickness through the distal end of the bowel, 2 cm proximally through the seromuscular layer, and then through subcuticular space.",
"    <br>",
"     (B) During the tying of the sutures, the distal end is everted unto itself.",
"     <br>",
"      (C) The matured, everted, Brooke end ileostomy with the sutures at the mucocutaneous junction.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_497=[""].join("\n");
var outline_f0_31_497=null;
var title_f0_31_498="Subjective global assessment form";
var content_f0_31_498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 615px\">",
"   <div class=\"ttl\">",
"    Evaluation form for subjective global assessment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 595px; height: 784px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (A) Well nourished",
"    </strong>",
"    _____.",
"    <br>",
"     <strong>",
"      (B) Mild/moderate undernutrition",
"     </strong>",
"     _____.",
"     <br>",
"      <strong>",
"       (C) Severe undernutrition",
"      </strong>",
"      _____.",
"      <br>",
"       The subjective global assessment (SGA) score is a subjective score. Each medical history and physical examination paramater is rated by the clinician as A (well-nourished), B (moderately malnourished), or C (severly malnourished). The ratings for each of the parameters are then used as a guide to determine the patient's subjecitve SGA score. For example, if a patient has more B or C ratings than A ratings, the patient is more likely to be malnourished.",
"       <div class=\"footnotes\">",
"        %: percent.",
"       </div>",
"       <div class=\"reference\">",
"        Reproduced with permission from: Sacks GS, Dearman K, Replogle WH, et al. Use of subjective global assessment to identify nutrition-associated complications and death in geriatric long-term care facility residents. J Am Coll Nutr 2000; 19:570. Copyright &copy; 2000 American College of Nutrition.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_498=[""].join("\n");
var outline_f0_31_498=null;
var title_f0_31_499="Medications for the prevention of breast cancer";
var content_f0_31_499=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/31/499/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/499/contributors\" id=\"au4385\">",
"       Wendy Y Chen, MD, MPH",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/499/contributors\" id=\"au4356\">",
"       Graham A Colditz, MD, DrPh",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/31/499/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/499/contributors\" id=\"se4959\">",
"       Daniel F Hayes, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/31/499/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/499/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?0/31/499?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Approximately 210,000 women in the United States are newly diagnosed with breast cancer each year. Certain risk factors may increase the likelihood that a woman will develop breast cancer, including advancing age, a strong family history of breast cancer, and having a precancerous breast condition, such as lobular carcinoma in situ (LCIS).",
"    </p>",
"    <p>",
"     Based upon a careful risk assessment, healthcare providers sometimes recommend therapy with one of several medications to reduce the chance of developing breast cancer for women at increased risk. These medications are called selective estrogen receptor modulator (SERM), of which there are two: tamoxifen and raloxifene. Another group of medications, called the aromatase inhibitors, such as exemestane, are also being studied for breast cancer prevention, though none are approved for this indication.",
"    </p>",
"    <p>",
"     These medications only work to prevent tumors that are known to be responsive to female hormones, which can be identified by the presence of hormone receptors. Tumors that have hormone receptors are called either ER-positive (short for estrogen-receptor positive) or PR-positive (short for progestin-receptor positive).",
"    </p>",
"    <p>",
"     The following is a discussion of studies evaluating the effectiveness of both SERMs and aromatase inhibitors for breast cancer prevention in women without a history of breast cancer, possible adverse effects of treatment, and information about which women should consider taking one of these agents. The role of SERMs and the aromatase inhibitors in women with a history of breast cancer is covered separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/52/26437?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/2/39970?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)\"",
"     </a>",
"     .) &nbsp;",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW DO PREVENTIVE AGENTS WORK?",
"     </span>",
"    </p>",
"    <p>",
"     The preventive agents all work by interfering with the effects of the female hormone estrogen. SERMs work by blocking the effects of estrogen on breast tissue. Aromatase inhibitors work by blocking an enzyme (aromatase) that is responsible for producing estrogen within the body in postmenopausal women (or women after menopause).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      EFFECTIVENESS",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14120212\">",
"     <span class=\"h2\">",
"      SERMs",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Tamoxifen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Multiple studies have examined the effectiveness of tamoxifen for the prevention of breast cancer. Overall, these studies suggest that tamoxifen can prevent hormone positive breast cancers from developing in women at risk for the disease. In general, tamoxifen, given daily for five years, reduces the risk of developing breast cancer by about one-half. Tamoxifen can be used in women before and after menopause. &nbsp;",
"    </p>",
"    <p>",
"     Despite the evidence that it reduces the risk of developing breast cancer in high-risk women, tamoxifen has not been widely accepted for breast cancer prevention. That is largely because there is no evidence that tamoxifen improves survival when given as a preventive treatment and because the medication has a small risk of serious adverse events, including uterine cancer and blood clots in the legs or lungs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Raloxifene",
"     </span>",
"     &nbsp;&mdash;&nbsp;Raloxifene is currently used for the prevention and treatment of osteoporosis (low bone density) in postmenopausal women. Several studies suggest that in postmenopausal women at high risk of developing breast cancer, raloxifene can reduce the risk of developing an invasive hormone-positive (ER-positive) breast cancer.",
"    </p>",
"    <p>",
"     In the STAR Breast Cancer Prevention Trial that directly compared tamoxifen and raloxifene, raloxifene was slightly less effective than tamoxifen at preventing breast cancer. On the other hand, raloxifene was associated with fewer of the most serious side effects associated with tamoxifen, including a lower risk of uterine cancer. Raloxifene has been tested only in postmenopausal women; its benefit in premenopausal women is unknown.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tamoxifen and raloxifene are not recommended for some women, including those who:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Have a history of blood clots in the legs or lungs (known as &ldquo;deep vein thrombosis&rdquo; or &ldquo;pulmonary embolism&rdquo;)",
"      </li>",
"      <li>",
"       Require anticoagulant or blood-thinning medications",
"      </li>",
"      <li>",
"       Smoke",
"      </li>",
"      <li>",
"       Are pregnant, planning on becoming pregnant, or breastfeeding (tamoxifen may cause birth defects if taken during pregnancy)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Women who use tamoxifen prior to menopause should use a non-hormonal method of birth control (such as condoms and a diaphragm), since hormonal methods of birth control, such as oral contraceptives, may alter the effectiveness of tamoxifen. A woman should immediately notify her doctor if she becomes pregnant while on tamoxifen. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Women who use tamoxifen or raloxifene should be closely monitored by their healthcare provider. In particular, women should:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Have an annual gynecologic examination, including a breast examination and, if recommended, a yearly mammogram and Pap smear (screening of the cervix for cancerous or precancerous cells). Any woman who finds a new breast lump should speak with her healthcare provider about the need for diagnostic testing (mammogram, ultrasound, biopsy).",
"      </li>",
"      <li>",
"       Immediately report any abnormal gynecologic symptoms, such as menstrual irregularities, abnormal vaginal bleeding or spotting, staining, or pelvic pressure or pain. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"        \"Patient information: Abnormal uterine bleeding (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Seek immediate medical care if they develop signs or symptoms of a blood clot, such as calf tenderness, swelling, pain, or severe, unexplained breathlessness or a fast heart rate.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14120244\">",
"     <span class=\"h2\">",
"      Aromatase inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;Of the aromatase inhibitors used in the treatment of breast cancer (ie, anastrazole, letrozole, exemestane), only one trial that looked at exemestane has been published. In this trial, exemestane reduced the risk of breast cancer by approximately 65 percent. Questions remain as to long-term effects of these drugs on bone loss and cardiovascular risk. Furthermore, joint and muscle symptoms associated with aromatase inhibitors may limit patient acceptance of this medication for preventive purposes. However, none of the aromatase inhibitors, including exemestane, are approved for breast cancer prevention.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Who should consider medication for breast cancer prevention?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Guidelines from expert groups recommend that the risks and benefits of breast cancer prevention be discussed with premenopausal and postmenopausal women who are at high risk for the disease [",
"     <a class=\"abstract\" href=\"UTD.htm?0/31/499/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]. Appropriate candidates for breast cancer prevention include the following groups: &nbsp;",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women over the age of 60.",
"      </li>",
"      <li>",
"       Women with certain high-risk conditions found on breast biopsy, such as lobular carcinoma in situ (LCIS) or atypical ductal or lobular hyperplasia.",
"      </li>",
"      <li>",
"       Women between the ages of 35 and 59 years who have a calculated five-year risk of developing breast cancer of 1.66 percent or higher, according to a system called the Gail model. The Gail model uses a woman's current age, age at first menstrual period, age at first live birth, the number of first-degree relatives with breast cancer, and the number and pathologic findings of any breast biopsies to estimate the probability of breast cancer over time.",
"       <br/>",
"       <br/>",
"       A program called the Breast Cancer Risk Assessment Tool is available to calculate an individual woman's risk according to the Gail model [",
"       <a class=\"abstract\" href=\"UTD.htm?0/31/499/abstract/4\">",
"        4",
"       </a>",
"       ]. Risk assessment tools such as these were developed for health professionals; patients who use them on their own should speak with their clinician for help interpreting the results. In addition, the presence of breast cancer risk factors does",
"       <strong>",
"        not",
"       </strong>",
"       mean that cancer is inevitable. Many women with risk factors never develop breast cancer.",
"       <br/>",
"       <br/>",
"       An important issue is that the Gail model does not consider the risk of cancer associated with inherited breast cancer-predisposing genes such as BRCA1 and BRCA2. Preliminary data suggest that tamoxifen helps reduce the risk of breast cancer in women with BRCA mutations, but benefit may be limited to certain women who inherit these mutations. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"        \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Choice of agent: tamoxifen, raloxifene, or an aromatase inhibitor?",
"     </span>",
"    </p>",
"    <p>",
"     For women who choose to pursue breast cancer prevention, the choice of agent depends on a number of factors, including her menopausal status, the side effects expected with each agent, and cost. &nbsp;",
"    </p>",
"    <p>",
"     Postmenopausal women have the choice between tamoxifen or raloxifene. There are no studies comparing them against each other as primary prevention. In addition, aromatase inhibitors are not approved for primary prevention. Questions remain as to long-term effects of an aromatase inhibitor on bone loss and cardiovascular risk.",
"    </p>",
"    <p>",
"     If a SERM is chosen, tamoxifen appears to be more effective than raloxifene in preventing breast cancer. However, raloxifene has fewer serious side effects. Models to assess benefit and risk of tamoxifen versus raloxifene in individual women are available. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"      \"Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Tamoxifen is the only option for premenopausal women who choose to pursue breast cancer prevention. At present, raloxifene is not used for breast cancer prevention in premenopausal women because of the lack of data regarding safety in this population. In addition, aromatase inhibitors are generally not used in premenopausal women because they can actually increase estrogen production in women whose ovaries are still producing the hormone.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H864777681\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5513621\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/26/3492?source=see_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5513629\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/6/44134?source=see_link\">",
"      Patient information: Factors that modify breast cancer risk in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/49/25366?source=see_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/18/22820?source=see_link\">",
"      Patient information: Abnormal uterine bleeding (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H864777688\">",
"     <span class=\"h2\">",
"      Professional-level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41576?source=see_link\">",
"      Managing the side effects of tamoxifen",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"      Screening for breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44246?source=see_link\">",
"      Selective estrogen receptor modulators and aromatase inhibitors for breast cancer prevention",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People Living With Cancer: The official patient information",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Web site of the American Society of Clinical Oncology",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Susan G. Komen Breast Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.komen.org/\">",
"      www.komen.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?0/31/499?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/499/abstract/1\">",
"      U.S. Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med 2002; 137:56.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for cancer prevention from the National Comprehensive Cancer Network (NCCN) available online at www.nccn.org (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/499/abstract/3\">",
"      Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27:3235.",
"     </a>",
"    </li>",
"    <li>",
"     Breast cancer risk asssessment tool. www.cancer.gov/bcrisktool/ (Accessed on March 20, 2012).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f0_31_499=[""].join("\n");
var outline_f0_31_499=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW DO PREVENTIVE AGENTS WORK?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           EFFECTIVENESS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f0_31_500="SVC syndrome appearance";
var content_f0_31_500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superior vena cava syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A prominent venous pattern on the chest, facial edema, and a plethoric appearance is present in this man with SVC obstruction from lung cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Midthun, DE, et al. Clinical presentation of lung cancer. Lung Cancer 1996; :421. Copyright &copy; Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_500=[""].join("\n");
var outline_f0_31_500=null;
var title_f0_31_501="Magnesium chloride: Pediatric drug information";
var content_f0_31_501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium chloride: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/22/24933?source=see_link\">",
"    see \"Magnesium chloride: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24004?source=see_link\">",
"    see \"Magnesium chloride: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chloromag&reg;;",
"     </li>",
"     <li>",
"      Mag 64&reg; [OTC];",
"     </li>",
"     <li>",
"      Mag Delay&trade; [OTC];",
"     </li>",
"     <li>",
"      Slow-Mag&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1022932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Magnesium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11443859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypomagnesemia: I.V.: Magnesium chloride: 0.2-0.4 mEq/kg/dose every 8-12 hours for 2-3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Daily maintenance magnesium: I.V.: 0.25-0.5 mEq magnesium/kg/day  (",
"     <b>",
"      Note:",
"     </b>",
"     mEq denotes amount of magnesium ion only not the total salt form.)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1022941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/22/24933?source=see_link\">",
"      see \"Magnesium chloride: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypomagnesemia: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M., I.V.: Magnesium chloride: 0.2-0.4 mEq/kg/dose every 4-6 hours for 3-4 doses; maximum single dose: 16 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Achieving optimal magnesium levels using oral therapy may be difficult due to the propensity for magnesium to cause diarrhea; I.V. replacement may be more appropriate particularly in situations of severe deficit:",
"     <b>",
"      Magnesium chloride:",
"     </b>",
"     10-20 mg/kg elemental magnesium per dose up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dietary supplement: Adults: Oral: (Mag 64&reg;, Mag Delay&trade;, Slow-Mag&reg;): 2 tablets once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Daily maintenance magnesium: I.V.: Magnesium chloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;45 kg: 0.25-0.5 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents &gt;45 kg and Adults: 0.2-0.5 mEq/kg/day or 3-10 mEq/1000 kcal/day (maximum: 8-20 mEq/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute receiving magnesium should have serum magnesium levels monitored.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hexahydrate: 200 mg/mL (50 mL) [equivalent to elemental magnesium 1.97 mEq/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloromag&reg;: 200 mg/mL (50 mL) [contains aluminum, benzyl alcohol; equivalent to elemental magnesium 1.97 mEq/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, delayed release, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag 64&reg;: Elemental magnesium 64 mg [sugar free; contains elemental calcium 112 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag Delay&trade;: Elemental magnesium 64 mg [contains elemental calcium 112 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, enteric coated, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Slow-Mag&reg;: Elemental magnesium 71.5 mg [contains elemental calcium 119 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3416485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Tablet: Take with full glass of water; do not chew or crush sustained release formulations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Intermittent infusion: Dilute to a concentration of 0.5 mEq/mL (maximum concentration: 1.6 mEq/mL, and infuse over 2-4 hours; do not exceed 1 mEq/kg/hour;  in severe circumstances, half of the dosage to be administered may be infused over the first 15-20 minutes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1022933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypomagnesemia; dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F190795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Gastrointestinal: Diarrhea (excessive oral doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3416478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to magnesium salt(s) or any component; serious renal impairment, myocardial damage, heart block; patients with colostomy or ileostomy, intestinal obstruction, impaction, or perforation, appendicitis, abdominal pain",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3416480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function (accumulation of magnesium may lead to magnesium intoxication); use with caution in digitalized patients (may alter cardiac conduction leading to heart block). The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3416479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium;",
"     <b>",
"      incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Magnesium chloride injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid or use magnesium chloride injection with caution in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3011375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3011366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Animal reproduction studies have not been conducted. Magnesium crosses the placenta; serum levels in the fetus correlate with those in the mother (Idama, 1998; Osada, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3416486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium, deep tendon reflexes, respiratory rate, renal function, blood pressure, stool output (laxative use)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1022940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates and Infants: 1.5-2.3 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1.5-2.0 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 1.4-2.0 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3416482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body. There are at least 300 enzymes which are dependent upon magnesium for normal functioning. Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol. Magnesium is necessary for the maintaining of serum potassium and calcium levels due to its effect on the renal tubule. In the heart, magnesium acts as a calcium channel blocker. It also activates sodium potassium ATPase in the cell membrane to promote resting polarization and produce arrhythmias.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3416484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Up to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal with unabsorbed drug excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3426352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium chloride 500 mg = 59 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium= 4.9 mEq magnesium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Magnesium Content of Magnesium Salts",
"     </caption>",
"     <col align=\"left\" width=\"190\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/500 mg salt)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/500 mg salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium L-aspartate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium oxide",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         302",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse effects associated with elevated serum magnesium concentrations may include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;3 mg/dL: Blocked peripheral neuromuscular transmission leading to anticonvulsant effects, depressed CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;5 mg/dL: Depressed deep tendon reflexes, flushing, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;12 mg/dL: Complete heart block, respiratory paralysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Department Health &amp; Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, &ldquo;Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , National Academy of Sciences, Washington, DC, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, at al, \"Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/31/501/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12976 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-0C172D990F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_501=[""].join("\n");
var outline_f0_31_501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022932\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443859\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022941\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190777\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190767\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416485\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022933\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190795\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416478\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416480\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416479\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299630\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011375\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190774\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011366\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416486\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1022940\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416482\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416484\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426352\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12976|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/22/24933?source=related_link\">",
"      Magnesium chloride: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24004?source=related_link\">",
"      Magnesium chloride: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_31_502="Diuretic-induced hyponatremia";
var content_f0_31_502=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diuretic-induced hyponatremia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/502/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/502/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/502/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/502/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/502/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/502/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/31/502/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is an occasional but potentially fatal complication of diuretic therapy. Virtually all cases of severe diuretic-induced hyponatremia have been due to a thiazide-type diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. A loop diuretic is much less likely to induce this problem unless the diuretic has induced volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/8\">",
"     8",
"    </a>",
"    ] or water intake is very high (since loop diuretics partially impair urinary diluting capacity).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difference in hyponatremic risk between thiazide-type and loop diuretics may be related to differences in their tubular site of action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39128?source=see_link\">",
"     \"Mechanism of action of diuretics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop diuretics inhibit sodium chloride (NaCl) reabsorption in the thick ascending limb of the loop of Henle. The reabsorption of NaCl without water in the medullary aspect of this segment is normally the first step in the generation of the hyperosmotic gradient in the medullary interstitium. In the presence of antidiuretic hormone (ADH), the highly concentrated interstitium allows water to be reabsorbed in the medullary collecting tubule down the favorable osmotic gradient between the tubular lumen and the interstitium, resulting in the excretion of a concentrated urine.",
"      <br/>",
"      <br/>",
"      Administration of a loop diuretic interferes with this process by impairing the accumulation of NaCl in the medulla. Thus, although the loop diuretic can increase ADH levels by inducing volume depletion, responsiveness to ADH is reduced because of the impairment in the medullary gradient [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/9\">",
"       9",
"      </a>",
"      ]. As a result, water retention and the development of hyponatremia will be limited, unless distal delivery is very low or water intake is very high.",
"     </li>",
"     <li>",
"      The thiazides, in comparison, act in the cortex in the distal tubule; as a result, they do not interfere with medullary function or with ADH-induced water retention. In addition, in vitro data indicate that thiazides increase water permeability and water reabsorption in the inner medullary collecting duct, an effect that is independent of ADH [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/10\">",
"       10",
"      </a>",
"      ]. In addition to water retention, the combination of increased sodium and potassium excretion (due to the diuretic) and enhanced water reabsorption (due to ADH) can result in the excretion of urine with a sodium plus potassium concentration higher than that of the plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/3\">",
"       3",
"      </a>",
"      ]. Loss of this fluid can directly promote the development of hyponatremia independent of the degree of water intake. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=see_link&amp;anchor=H5#H5\">",
"       \"Chapter 9B: Renal water excretion and reabsorption\", section on 'Electrolyte-free water reabsorption'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with other diuretic-induced fluid and electrolyte complications, hyponatremia often develops within the",
"    <strong>",
"     first one to two weeks of therapy",
"    </strong>",
"    if diuretic dose and dietary intake remain relatively constant (",
"    <a class=\"graphic graphic_figure graphicRef74940 \" href=\"UTD.htm?15/33/15901\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/1,3,11\">",
"     1,3,11",
"    </a>",
"    ]. After this period, the patient is in a new steady state in which further sodium and water losses do not occur. However, in many patients with diuretic-induced hyponatremia, the disorder first appears after many months of uncomplicated thiazide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. In these patients, perturbation of the steady state, such as an acute gastrointestinal or respiratory illness, an increase in diuretic dose, or the development of heart failure, may explain the hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=see_link\">",
"     \"Time course of loop and thiazide diuretic-induced electrolyte complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reproducibility of thiazide-induced hyponatremia was evaluated in a study of 11 elderly patients with a history of thiazide-induced hyponatremia to below 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2\">",
"     2",
"    </a>",
"    ]. Rechallenge with a single 50 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    lowered the plasma sodium concentration by 5 to 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the first six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2\">",
"     2",
"    </a>",
"    ]. A more pronounced effect was noted in another study of two elderly patients who had recovered from episodes of severe thiazide-induced hyponatremia (serum sodiums of 109 and 116",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/3\">",
"     3",
"    </a>",
"    ]. Rechallenge with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/32/1542?source=see_link\">",
"     metolazone",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or hydrochlorothiazide (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    resulted in a decrease in serum sodium from 142 to 124",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 36 hours in one patient, and from 133 to 120",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 37 hours in the other patient [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983318\">",
"    <span class=\"h2\">",
"     Increased water intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with thiazide-induced hyponatremia appear to have an underlying tendency to increased water intake (polydipsia). As an example, a study of 11 elderly patients with thiazide-induced hyponatremia and 10 healthy controls found that both the pre-thiazide serum sodium concentration (mean 138 versus 141",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and the urine osmolality (306 versus 513",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    were lower in those who developed hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impaired water excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, increased water intake will not lead to hyponatremia unless there is an impairment in water excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least four different mechanisms may contribute to diuretic-induced hyponatremia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume depletion can stimulate the release of ADH, leading to the production of a concentrated urine [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/1,3,8\">",
"       1,3,8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enhanced ADH release may be a secondary event induced by nausea and other neurologic symptoms.",
"     </li>",
"     <li>",
"      Thiazide diuretics may be associated with water retention that is independent of ADH [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients treated with diuretics may have a reduced glomerular filtration rate. This is a common contributor in the elderly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20658511#H20658511\">",
"       \"Assessment of kidney function\", section on 'Change in GFR with aging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elderly patients generally have a reduced ability to excrete a water load, an effect that is most prominent in those who have previously developed thiazide-induced hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/13\">",
"     13",
"    </a>",
"    ]. Why this occurs is not clear, but decreased intrarenal generation of prostaglandins may be important [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/13\">",
"     13",
"    </a>",
"    ]. A defect in water excretion due to prostaglandin deficiency would be amplified by thiazides, since the reabsorption of NaCl without water at the thiazide-sensitive site in the distal tubule normally lowers the urine osmolality. However, this mechanism would not explain the seeming rarity of hyponatremia with loop diuretics, which also inhibit urinary dilution. Perhaps the shorter duration of action of the loop diuretics protects against hyponatremia.",
"   </p>",
"   <p>",
"    Retention of water as a primary event can explain why many patients with thiazide-induced hyponatremia behave as if they are volume expanded: the body weight may initially increase [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2\">",
"     2",
"    </a>",
"    ]; the blood urea nitrogen and plasma creatinine concentration are generally low-normal [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]; and hypouricemia due to enhanced urinary uric acid excretion may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. All of these findings are similar to those in the syndrome of inappropriate ADH secretion (SIADH), which is also associated with initial volume expansion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Pathogenesis of hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the aggregate, these observations suggest that there are two different forms of diuretic-induced hyponatremia: one in which volume depletion stimulates the release of ADH; and another in which the patient may be slightly volume expanded [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients, the combination of sodium plus potassium loss and water retention accounts for essentially all of the fall in the plasma sodium concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. However, there are patients in whom this does not appear to be the case, raising the possibility that the hyponatremia is due in part to osmotic inactivation of sodium in the cells or perhaps bone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/15\">",
"     15",
"    </a>",
"    ]. How or if this actually occurs is not clear. A similar hypothesis was proposed in the syndrome of inappropriate ADH and then seemingly excluded by careful balance studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18442563\">",
"    <span class=\"h1\">",
"     INCIDENCE AND PATIENTS AT RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thiazide-induced hyponatremia is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The best data come from a retrospective cohort study of 2613 newly treated hypertensive patients followed for 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/18\">",
"     18",
"    </a>",
"    ]. Hyponatremia, defined as a serum sodium of 130",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    or less, developed in 66 of 220 patients initiated on a thiazide (30 percent) compared with 422 of 2393 patients started on alternate therapy (18 percent). Most cases of hyponatremia in patients taking thiazides occurred in the first three months of treatment. However, the risk of hyponatremia continued to be higher in the group exposed to thiazides throughout the 10 years of observation. Among those that developed hyponatremia, the median time to diagnosis was 1.75 years, emphasizing the importance of continued follow-up of patients started on thiazide diuretics. The incidence of hyponatremia associated with thiazide therapy was slightly, but not significantly, more common with advancing age (ie, 37 versus 24 percent comparing those above and below 60 years of age). After taking into account other risk factors for hyponatremia, thiazide therapy was associated with one excess case of hyponatremia for every 15 patients treated. &nbsp;",
"   </p>",
"   <p>",
"    The association of thiazide-induced hyponatremia with older age, particularly those with low body weight, has been noted in other studies as well [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/1-5,12,20\">",
"     1-5,12,20",
"    </a>",
"    ]. As an example, a case controlled study in hospitalized patients found that patient age and body mass were independent risk factors for thiazide-induced hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/5\">",
"     5",
"    </a>",
"    ]. Each 10-year increment of age was associated with a twofold increase in risk, and every 5 kg increment in body mass decreased the odds ratio by 27 percent. Alcoholics, particularly beer drinkers, and patients with psychogenic polydipsia who depend on the excretion of maximally dilute urine to maintain water balance are also at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of diuretic-induced hyponatremia are similar to those of other causes of hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hyponatremia typically begins soon after the onset of thiazide therapy and corrects over a period of days to two weeks after the cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Most patients do not exhibit signs of volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diuretic-induced hyponatremia is rarely, if ever, associated with cerebral edema severe enough to cause herniation of the brain. This was illustrated in a series of 223 patients hospitalized for symptomatic hyponatremia due to thiazide diuretics; the mean plasma sodium was 115",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/6\">",
"     6",
"    </a>",
"    ]. The major symptoms were malaise, lethargy, dizzy spells, and vomiting, all of which are well described manifestations of severe hyponatremia. There was only a 1 percent incidence of seizures and no cases of herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The older literature includes reports of brain damage in outpatients with thiazide-induced hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. However, at the time of the study, the consequences of overly rapid correction were unknown. The reported patients were all treated with hypertonic saline, increasing the plasma sodium concentration by more than 25",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 48 hours, a rate of correction now known to be associated with osmotic demyelination in the brain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=see_link\">",
"     \"Osmotic demyelination syndrome and overly rapid correction of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of diuretic-induced hyponatremia consists of discontinuing the diuretic and administering either isotonic saline or, if the hyponatremia is severe or symptomatic, hypertonic saline. There is a potential risk of overly rapid correction of the hyponatremia with either regimen. Once the diuretic has been cleared and the patient becomes euvolemic, ADH release will be appropriately suppressed, resulting in the excretion of a dilute urine, which can lead to rapid excretion of the excess water. Thus, patients with moderate to severe hyponatremia must be monitored carefully during treatment to minimize the risk of osmotic demyelination [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/1\">",
"     1",
"    </a>",
"    ]. Preemptive administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    has been used to prevent the excretion of dilute urine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"     \"Overview of the treatment of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven way to identify patients at risk of developing hyponatremia after diuretic therapy, making prevention difficult. Nevertheless, it may be prudent to avoid thiazide diuretics in beer drinkers and patients with psychogenic polydipsia and to measure the plasma sodium concentration within a few days after therapy has begun in elderly patients, especially those with a low body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/502/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. A thiazide diuretic should generally",
"    <strong>",
"     not",
"    </strong>",
"    be used in patients who have had a previous episode of hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=see_link\">",
"       \"Patient information: Hyponatremia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9602708\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thiazide diuretics are more likely to cause hyponatremia than loop diuretics because they impair NaCl reabsorption in the distal convoluted tubule. As a result, there is an intact medullary concentration gradient, which is dependent on NaCl reabsorption in the loop, and patients treated with thiazide diuretics can excrete a concentrated urine if ADH is present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thiazide-induced hyponatremia most commonly occurs in elderly patients, particularly those with a low body mass. (See",
"      <a class=\"local\" href=\"#H18442563\">",
"       'Incidence and patients at risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with thiazide-induced hyponatremia often appear clinically euvolemic, sharing many features in common with patients with the syndrome of inappropriate ADH secretion. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment consists of stopping the diuretic and administering either isotonic saline or, if the hyponatremia is severe or symptomatic, hypertonic saline. Patients with thiazide-induced hyponatremia are at risk of overly rapid correction because the ability to dilute the urine is restored once the effect of the diuretic clears and the patient becomes euvolemic. Thus, careful monitoring is needed during therapy to avoid osmotic demyelination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/1\">",
"      Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia. Review and analysis of 129 reported patients. Chest 1993; 103:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/2\">",
"      Friedman E, Shadel M, Halkin H, Farfel Z. Thiazide-induced hyponatremia. Reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med 1989; 110:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/3\">",
"      Ashraf N, Locksley R, Arieff AI. Thiazide-induced hyponatremia associated with death or neurologic damage in outpatients. Am J Med 1981; 70:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/4\">",
"      Fichman MP, Vorherr H, Kleeman CR, Telfer N. Diuretic-induced hyponatremia. Ann Intern Med 1971; 75:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/5\">",
"      Chow KM, Szeto CC, Wong TY, et al. Risk factors for thiazide-induced hyponatraemia. QJM 2003; 96:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/6\">",
"      Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc 2004; 96:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/7\">",
"      Mozes B, Pines A, Werner D, et al. Thiazide-induced hyponatremia: an unusual neurologic course. South Med J 1986; 79:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/8\">",
"      Sonnenblick M, Rosin AJ. Significance of the measurement of uric acid fractional clearance in diuretic induced hyponatraemia. Postgrad Med J 1986; 62:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/9\">",
"      Szatalowicz VL, Miller PD, Lacher JW, et al. Comparative effect of diuretics on renal water excretion in hyponatraemic oedematous disorders. Clin Sci (Lond) 1982; 62:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/10\">",
"      C&eacute;sar KR, Magaldi AJ. Thiazide induces water absorption in the inner medullary collecting duct of normal and Brattleboro rats. Am J Physiol 1999; 277:F756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/11\">",
"      Maronde RF, Milgrom M, Vlachakis ND, Chan L. Response of thiazide-induced hypokalemia to amiloride. JAMA 1983; 249:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/12\">",
"      Sharabi Y, Illan R, Kamari Y, et al. Diuretic induced hyponatraemia in elderly hypertensive women. J Hum Hypertens 2002; 16:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/13\">",
"      Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994; 5:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/14\">",
"      Decaux G, Schlesser M, Coffernils M, et al. Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia. Clin Nephrol 1994; 42:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/15\">",
"      Johnson JE, Wright LF. Thiazide-induced hyponatremia. South Med J 1983; 76:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/16\">",
"      Cooke CR, Turin MD, Walker WG. The syndrome of inappropriate antidiuretic hormone secretion (SIADH): pathophysiologic mechanisms in solute and volume regulation. Medicine (Baltimore) 1979; 58:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/17\">",
"      Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J Physiol 1994; 267:R1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/18\">",
"      Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med 2011; 124:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/19\">",
"      Clayton JA, Rodgers S, Blakey J, et al. Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 2006; 61:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/502/abstract/20\">",
"      Gross P, Palm C. Thiazides: do they kill? Nephrol Dial Transplant 2005; 20:2299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2288 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-7F4984794A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_502=[""].join("\n");
var outline_f0_31_502=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9602708\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983318\">",
"      Increased water intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impaired water excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18442563\">",
"      INCIDENCE AND PATIENTS AT RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9602708\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2288\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2288|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/33/15901\" title=\"figure 1\">",
"      Time course of diuretic action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=related_link\">",
"      Chapter 9B: Renal water excretion and reabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39128?source=related_link\">",
"      Mechanism of action of diuretics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10074?source=related_link\">",
"      Osmotic demyelination syndrome and overly rapid correction of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/20/9537?source=related_link\">",
"      Patient information: Hyponatremia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/45/6868?source=related_link\">",
"      Time course of loop and thiazide diuretic-induced electrolyte complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_31_503="Stapling devices";
var content_f0_31_503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    Stapling devices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 568px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Roticular disoposable surgical stapler with disposable loading unit. (B) Skin staple gun and cartridge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_503=[""].join("\n");
var outline_f0_31_503=null;
var title_f0_31_504="Minor Vibrio and Vibrio-like species associated with human disease";
var content_f0_31_504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Minor Vibrio and Vibrio-like species associated with human disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/504/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/504/contributors\">",
"     J Glenn Morris, Jr, MD, MPH&amp;TM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/504/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/504/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/504/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/504/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/31/504/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H631646146\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibrios are ubiquitous environmental Gram-negative rods, with well over 100 species currently recognized. Among these species, 10 have been isolated from humans. The species responsible for the most serious diseases are V. cholerae (V. cholerae",
"    <span class=\"nowrap\">",
"     O1/O139",
"    </span>",
"    strains causing the disease cholera and other V. cholerae strains linked with diarrhea, wound infections, and septicemia), V. parahaemolyticus, and V. vulnificus.",
"   </p>",
"   <p>",
"    Four additional species (V. mimicus, V. fluvialis, V. furnissii, V. alginolyticus) clearly have pathogenic potential for humans but cause illness that generally is less severe. Two closely related species that were originally classified in the genus Vibrio but have undergone a change in name on the basis of recent taxonomic studies, Grimontia hollisae (formerly Vibrio hollisae) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/1\">",
"     1",
"    </a>",
"    ], and Photobacterium damsela (formerly Vibrio damsela) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/2\">",
"     2",
"    </a>",
"    ], are also established human pathogens. Three species (V. metschnikovii, V. cincinnatiensis, and V. carchariae [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]) have primarily been the subject of case reports, and their significance as human pathogens remains to be determined.",
"   </p>",
"   <p>",
"    This topic discusses the microbiology, epidemiology, clinical manifestations, diagnosis and treatment of the six minor Vibrio and Vibrio-like species that have been associated with human disease. Infections due to the major Vibrio species are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link\">",
"     \"Overview of Vibrio cholerae infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18502?source=see_link\">",
"     \"Infections due to non-O1/O139 Vibrio cholerae\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27878?source=see_link\">",
"     \"Vibrio parahaemolyticus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link\">",
"     \"Vibrio vulnificus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10851452\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY COMMON TO VIBRIO SPECIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All Vibrio species are free-living microorganisms in marine and estuarine environments. They are sensitive to temperature, with numbers of microorganisms in the environment increasing during warmer, summer months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/8\">",
"     8",
"    </a>",
"    ]. As an example, the number of Vibrio species isolated from human infections in the United States and reported to the Center for Disease Control peaks during the months of May to September. Approximately 25 percent of the 825 non-toxigenic V. cholerae Vibrio isolates reported in the US in 2009 occurred in August (",
"    <a class=\"graphic graphic_figure graphicRef82927 \" href=\"UTD.htm?4/60/5070\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Vibrio species are associated mainly with gastroenteritis, wound infection, and occasionally bacteremia. V. mimicus, V. fluvialis, V. furnissii, and Grimontia hollisae primarily cause gastroenteritis. V. alginolyticus and Photobacterium damsela primarily cause wound infections (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646153\">",
"    <span class=\"h1\">",
"     SPECIES THAT PRIMARILY CAUSE DIARRHEA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646161\">",
"    <span class=\"h2\">",
"     V. mimicus",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. mimicus, identified as a separate species in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/9\">",
"     9",
"    </a>",
"    ], was initially classified as &ldquo;atypical sucrose-negative V. cholerae.&rdquo; The species &ldquo;mimics&rdquo; V. cholerae in many biochemical tests, hence the name. Comparative genomic analysis suggests that V. mimicus and V. cholerae diverged from a common ancestor derived from the strain that caused the sixth cholera pandemic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/10\">",
"     10",
"    </a>",
"    ]. Despite the close genetic relationship with V. cholerae, V. mimicus do not cause epidemic cholera-like disease. Fewer than 10 percent of clinical isolates, and less than 1 percent of environmental isolates, produce cholera toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/11\">",
"     11",
"    </a>",
"    ]. Strains do, however, carry a variety of possible virulence factors, including genes for a type III secretion system that can be seen in V. parahaemolyticus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27878?source=see_link&amp;anchor=H2#H2\">",
"     \"Vibrio parahaemolyticus infections\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646168\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of seafood is the main risk factor for V. mimicus gastrointestinal infection. The microorganism has been isolated from shrimp and other shellfish in fish markets in Malaysia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/13\">",
"     13",
"    </a>",
"    ] and from mussels in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/14\">",
"     14",
"    </a>",
"    ]. In the US, occurrence of V. mimicus diarrhea has been associated with eating raw oysters and other shellfish, including crayfish [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In a large Thai outbreak, &ldquo;fish soup&rdquo; was implicated as the vehicle of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/17\">",
"     17",
"    </a>",
"    ], and infection has been linked to consumption of raw turtle eggs in Costa Rica [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/18\">",
"     18",
"    </a>",
"    ]. In a pattern analogous to that seen with",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae, the organism is likely to be introduced into communities through seafood, with further transmission in the developing world related to fecal contamination of food and water sources. Wound and ear infections occur to a lesser extent and are generally seen in the setting of exposure to estuarine waters [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/15\">",
"     15",
"    </a>",
"    ], which serve as a reservoir for the microorganism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646175\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenteritis, with typical symptoms of diarrhea, nausea, vomiting, and abdominal cramps, is the primary clinical manifestation of V. mimicus infection. Wound and ear infections occur rarely, as does bacteremia (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In an initial case series (which was probably biased toward more severe cases), median duration of illness was six days, with 44 percent of patients having fever, and 16 percent having bloody diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/15\">",
"     15",
"    </a>",
"    ]. Approximately 55 percent of V. mimicus clinical isolates in the US reported to CDC between 2004 and 2009 were from hospitalized patients (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ). In the Thai outbreak involving over 400 persons, symptoms were milder, with 91 percent reporting diarrhea, 66 percent abdominal pain, and 27 percent vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/17\">",
"     17",
"    </a>",
"    ]. Symptoms resolved in two-thirds",
"    <sup>",
"    </sup>",
"    of these patients within 36 hours, with less than a third seeking medical attention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646204\">",
"    <span class=\"h2\">",
"     V. fluvialis",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. fluvialis was identified as a separate species in 1981, with the name derived from the Latin for &ldquo;river,&rdquo; reflecting its early isolation from river and estuarine waters [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/19\">",
"     19",
"    </a>",
"    ]. Strains do not appear to produce cholera toxin. They have been shown to have",
"    <span class=\"nowrap\">",
"     cytopathic/cytotoxic",
"    </span>",
"    effects on HeLa cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/20\">",
"     20",
"    </a>",
"    ], and to cause fluid accumulation in rabbit ileal loops, and diarrhea and death in infant mice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. However, factors responsible for these effects are not well defined. V. fluvialis has been associated with high rates of bloody diarrhea, raising the possibility that it is invasive in the intestinal tract, despite reports that isolates are negative for invasiveness in laboratory testing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646211\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. fluvialis is widely distributed in the estuarine and marine environment and has been isolated from shellfish and fish, including fish in Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/24\">",
"     24",
"    </a>",
"    ], shrimp and other shellfish in fish markets in Malaysia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/13\">",
"     13",
"    </a>",
"    ], and mussels in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/14\">",
"     14",
"    </a>",
"    ]. It is also recognized as an important pathogen for some marine species, with &ldquo;V. fluvialis-like&rdquo; strains identified as the cause of &ldquo;limp lobster&rdquo; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, V. fluvialis has been linked with large outbreaks in Bangladesh and India, including outbreaks of diarrheal disease after the major cyclone Aila [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/23,26\">",
"     23,26",
"    </a>",
"    ]. In the US, it is a relatively common Vibrio species isolated from patients. In reports from Bangladesh and India, cases have been concentrated in children and persons aged 55 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. Similar age-related incidence patterns were not observed in studies in Indonesia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/27\">",
"     27",
"    </a>",
"    ]. In a pattern analogous to that seen with",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae, the organism is likely to be introduced into human populations through seafood or water contact, with further transmission in the developing world related to fecal contamination of food and water sources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646218\">",
"    <span class=\"h3\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenteritis is the primary clinical manifestation of V. fluvialis infection. Infections at other sites, including wounds and ears, also occur, with rare reports of bacteremia and death (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ). Among 100 persons with &ldquo;moderate to severe&rdquo; illness following cyclone Aila in whom V. fluvialis was implicated as the etiologic agent, symptoms included watery diarrhea (86 percent of patients), bloody diarrhea (62 percent), abdominal pain (57 percent), vomiting (41 percent), and fever (21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/26\">",
"     26",
"    </a>",
"    ]. In an earlier outbreak in Bangladesh (1976-77), 75 percent of patients were found to have blood cells and leukocytes in their stools on microscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/23\">",
"     23",
"    </a>",
"    ]. The duration of diarrhea ranged from 16 to 80 hours, with antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646247\">",
"    <span class=\"h2\">",
"     V. furnissii",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. furnissii, initially identified as biovar II for V. fluvialis, was designated as a separate species in 1983 [10]. A complete genome sequence has been reported for an environmental strain. It lacked the gene for cholera toxin, other cholera toxin-related toxins, and genes encoding a type III secretion system [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The organism can be isolated from the environment, and has been isolated from mussels in Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/29\">",
"     29",
"    </a>",
"    ]. It has been retrospectively identified as the cause of at least one outbreak (gastroenteritis on an airplane flight from Tokyo to Seattle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/30\">",
"     30",
"    </a>",
"    ]), has been linked with gastroenteritis in Peru [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/31\">",
"     31",
"    </a>",
"    ] and Indonesia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/27\">",
"     27",
"    </a>",
"    ], and has been reported as the cause of bacteremia in a diabetic patient in Virginia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/32\">",
"     32",
"    </a>",
"    ]. However, its role as a pathogen remains somewhat controversial, particularly as in the Peru study, it was isolated more frequently from persons who were asymptomatic than from persons with diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646262\">",
"    <span class=\"h2\">",
"     Grimontia (Vibrio) hollisae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Grimontia hollisae, initially known as Vibrio hollisae, was designated as a separate species in 1982. G. hollisae is known to have a type III secretion system and produce a thermostable direct hemolysin very similar to that found in V. parahaemolyticus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G. hollisae has been isolated from the environment in Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/34\">",
"     34",
"    </a>",
"    ] and from mussels in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/35\">",
"     35",
"    </a>",
"    ], but reports are limited; it is unclear whether this reflects a decreased environmental presence compared with Vibrio species or technical problems in environmental isolation. It has been associated primarily with sporadic cases of gastroenteritis (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ), and there is a suggestion that illness is associated with consumption of seafood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Cases appear to be more common in North America, although isolation from patients with diarrhea has been reported from Indonesia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/27\">",
"     27",
"    </a>",
"    ], and a case of bacteremia has been reported from Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/36\">",
"     36",
"    </a>",
"    ]. Of five patients with bacteremia reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/38\">",
"     38",
"    </a>",
"    ], three had a history of underlying liver disease, similar to the pattern seen with",
"    <span class=\"nowrap\">",
"     non-O1/non-O139",
"    </span>",
"    V. cholerae and V. vulnificus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646285\">",
"    <span class=\"h1\">",
"     SPECIES THAT PRIMARILY CAUSE WOUND INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646293\">",
"    <span class=\"h2\">",
"     V. alginolyticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;V. alginolyticus is known to produce extracellular proteases and collagenases, which may contribute to its virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/39\">",
"     39",
"    </a>",
"    ]. It has also been found to have a type III secretion system that has been linked with the ability of the microorganism to cause rapid apoptosis, cell rounding, and osmotic lysis of fish cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    V. alginolyticus is widely distributed in the environment [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], has been isolated from fish and shellfish [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/43\">",
"     43",
"    </a>",
"    ], and is recognized as a pathogen for fish. It is the most common cause of Vibrio-associated wound infections in the United States (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ). It has been associated with otitis, and rare cases of bacteremia are reported, almost always associated with wound infections, and generally in immunocompromised or burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Wound infections and otitis are almost all associated with exposure to marine or estuarine waters. In contrast to other Vibrio species, it is only rarely isolated from stool, and it is unclear that it is able to cause gastrointestinal disease in humans.",
"   </p>",
"   <p>",
"    In a study in Western Australia, V. alginolyticus was isolated from 20 of 36 samples (56 percent) taken from infected superficial wounds contaminated with seawater [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/46\">",
"     46",
"    </a>",
"    ]. Most infections cleared within one or two days without the use of antibiotics. The general lack of severity associated with V. alginolyticus infections is reflected in the fact that in the US from 2004 to 2009, only three deaths were reported out of the 386 patients with V. alginolyticus infection (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ). In a 10-year study from Florida, no deaths were reported among 131 infections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H631646308\">",
"    <span class=\"h2\">",
"     Photobacterium (Vibrio) damsela",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photobacterium damsela has gone through several name changes: originally designated as Vibrio damsela (based on its pathogenicity for damsel fish [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/47\">",
"     47",
"    </a>",
"    ]), it has been known as Listonella damsela, and is currently designated as P. damsela. It is a rare cause of wound infections in the United States (",
"    <a class=\"graphic graphic_table graphicRef82928 \" href=\"UTD.htm?3/15/3325\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/37\">",
"     37",
"    </a>",
"    ]. It shows fairly striking virulence in mice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/48\">",
"     48",
"    </a>",
"    ], and has been isolated from a fatal case of necrotizing fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10851583\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of these Vibrio species is established by isolation of the organism from the relevant clinical specimen, generally stool or wound culture. They can grow on standard media used for wound and blood cultures. Isolation of Vibrio species from stool generally requires a selective media to suppress growth of other organisms, such as thiosulfate, citrate, bile salts, and sucrose (TCBS). The laboratory should be alerted regarding cases of diarrhea in which illness due to Vibrio species is suspected so that the appropriate media can be used. Species identification is based on standard biochemical tests.",
"   </p>",
"   <p>",
"    Certain species have particular diagnostic characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      V. mimicus and P. damsela appear as green colonies on TCBS agar. V. cholerae, V. alginolyticus, V. fluvialis, and V. furnissii are yellow.",
"     </li>",
"     <li>",
"      V. fluvialis shows marked biochemical similarity to Aeromonas species. When the British Public Health Laboratories reviewed all of their old anaerogenic, lysine-decarboxylase-negative Aeromonas strains, they found that one-third were actually V. fluvialis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/19\">",
"       19",
"      </a>",
"      ]. Microbiologic identification schemes in current use in the United States will sometimes mistakenly identify V. fluvialis as Aeromonas [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/22\">",
"       22",
"      </a>",
"      ]. Where V. fluvialis is suspected, isolates should be screened for salt requirements (V. fluvialis grows in 6 to 7 percent sodium chloride, while Aeromonas generally does not) to help differentiate the two species.",
"     </li>",
"     <li>",
"      G. hollisae does NOT grow on TCBS agar, in contrast to Vibrio species. Isolation is possible on blood agar or marine agar but tends to be difficult, particularly from stool [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22319510\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22319517\">",
"    <span class=\"h2\">",
"     Diarrheal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume repletion is the most important element of therapy in patients with diarrheal disease and is best done through the oral route with solutions that contain water, salt, and sugar. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult with acute diarrhea in developed countries\", section on 'Oral rehydration solutions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although diarrhea associated with these Vibrio species is often mild and self-limited, antimicrobial therapy is reasonable in moderate to severe cases, particularly in V. fluvialis infections, given its association with blood and leukocytes in the stool. No controlled trials of therapy of these Vibrio species have been performed, and there are limited observational data. In the Thai outbreak of V. mimicus, patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/17\">",
"     17",
"    </a>",
"    ]; no outcome data were reported. Successful therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    has been reported in one case of severe diarrhea and sepsis with G. hollisae infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/38\">",
"     38",
"    </a>",
"    ]. However, among patients with cholera, antimicrobials are known to decrease the duration of diarrhea and the excretion of infectious organisms and may also have the same benefit in these Vibrio species. Based upon clinical trials in cholera and in vitro susceptibility data, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or a fluoroquinolone. Susceptibility testing should be done to confirm sensitivity to these agents. We typically use a single dose of doxycycline 300 mg orally or ciprofloxacin 1 g orally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of Vibrio cholerae infection\", section on 'Antimicrobial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22319573\">",
"    <span class=\"h2\">",
"     Wound infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on treatment of wound infections due to these Vibrio species. Treatment suggestions are based upon clinical experience. Serious wound infections generally require debridement and antimicrobial therapy. Mild wound infections generally respond well to local wound care and oral antibiotics. In the case of V. alginolyticus infections of superficial wounds, antibiotics may not be necessary, as reflected by the report from Australia in which most cases resolved spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/504/abstract/46\">",
"     46",
"    </a>",
"    ]. Based upon antibiotic susceptibility patterns and clinical response of other Vibrio species, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or a fluoroquinolone for severe wound infections and infections in immunocompromised hosts. Susceptibility testing should be done to confirm sensitivity to these agents. We typically use oral doxycycline 100 mg twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg twice daily. Duration of therapy is dictated by clinical response; most patients respond to five to seven days of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22319378\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vibrio species are naturally occurring marine and estuarine microorganisms that are found worldwide. They are sensitive to temperature, and infections peak during warmer, summer months. (See",
"      <a class=\"local\" href=\"#H10851452\">",
"       'Epidemiology common to Vibrio species'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      V. mimicus primarily causes gastroenteritis and is frequently linked to seafood ingestion, particularly raw or undercooked shellfish. It may also occur as a result of fecal contamination of food and water sources. (See",
"      <a class=\"local\" href=\"#H631646161\">",
"       'V. mimicus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      V. fluvialis primarily causes gastroenteritis and has been associated with large outbreaks in Bangladesh and India. Bloody diarrhea and fecal leukocytes are common in V. fluvialis infection. It is very similar biochemically to Aeromonas, with which it may be confused in the laboratory. (See",
"      <a class=\"local\" href=\"#H631646204\">",
"       'V. fluvialis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10851583\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      V. furnissii has been associated with gastroenteritis, although its role as a pathogen remains controversial. (See",
"      <a class=\"local\" href=\"#H631646247\">",
"       'V. furnissii'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Grimontia hollisae primarily causes gastroenteritis, although cases of bacteremia are reported. Infection has been linked to seafood ingestion. (See",
"      <a class=\"local\" href=\"#H631646262\">",
"       'Grimontia (Vibrio) hollisae'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10851583\">",
"       'Diagnosis'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      V. alginolyticus is the most common cause of Vibrio-associated wound infections in the US, and most infections are mild. Photobacterium damsel also causes wound infections, although more rarely. Infections with both are linked with exposure to marine or estuarine waters. (See",
"      <a class=\"local\" href=\"#H631646293\">",
"       'V. alginolyticus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H631646308\">",
"       'Photobacterium (Vibrio) damsela'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of these Vibrio species is established by isolation of the organism from the relevant clinical specimen, generally stool or wound culture. Vibrio species can grow on standard media for wound and blood cultures. For gastroenteritis cases, the laboratory should be alerted of the suspicion for Vibrio, as isolation from stool requires a selective media to suppress growth of other organisms. In contrast to Vibrio species, G. hollisae does NOT grow on TCBS, the standard selective media used in isolation of Vibrios from stool. It does grow on blood agar. (See",
"      <a class=\"local\" href=\"#H10851583\">",
"       'Diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Volume repletion is the most important element of therapy in patients with diarrheal disease due to Vibrio species. Wound infections require local wound care and possibly debridement. For patients with mild superficial wounds due to V. alginolyticus, we suggest initial observation without antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Antibiotics should be given to those with moderate to severe infections or an underlying immunosuppressive condition. For such patients, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      or a fluoroquinolone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This choice is based upon antibiotic susceptibility patterns and clinical response of other Vibrio species. (See",
"      <a class=\"local\" href=\"#H22319510\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/1\">",
"      Thompson FL, Hoste B, Vandemeulebroecke K, Swings J. Reclassification of Vibrio hollisae as Grimontia hollisae gen. nov., comb. nov. Int J Syst Evol Microbiol 2003; 53:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/2\">",
"      Smith SK, Sutton DC, Fuerst JA, Reichelt JL. Evaluation of the genus Listonella and reassignment of Listonella damsela (Love et al.) MacDonell and Colwell to the genus Photobacterium as Photobacterium damsela comb. nov. with an emended description. Int J Syst Bacteriol 1991; 41:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/3\">",
"      Bode RB, Brayton PR, Colwell RR, et al. A new Vibrio species, Vibrio cincinnatiensis, causing meningitis: successful treatment in an adult. Ann Intern Med 1986; 104:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/4\">",
"      Pavia AT, Bryan JA, Maher KL, et al. Vibrio carchariae infection after a shark bite. Ann Intern Med 1989; 111:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/5\">",
"      Jean-Jacques W, Rajashekaraiah KR, Farmer JJ 3rd, et al. Vibrio metschnikovii bacteremia in a patient with cholecystitis. J Clin Microbiol 1981; 14:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/6\">",
"      Farmer JJ 3rd, Hickman-Brenner FW, Fanning GR, et al. Characterization of Vibrio metschnikovii and Vibrio gazogenes by DNA-DNA hybridization and phenotype. J Clin Microbiol 1988; 26:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/7\">",
"      Dalsgaard A, Alarcon A, Lanata CF, et al. Clinical manifestations and molecular epidemiology of five cases of diarrhoea in children associated with Vibrio metschnikovii in Arequipa, Peru. J Med Microbiol 1996; 45:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/8\">",
"      Weis KE, Hammond RM, Hutchinson R, Blackmore CG. Vibrio illness in Florida, 1998-2007. Epidemiol Infect 2011; 139:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/9\">",
"      Davis BR, Fanning GR, Madden JM, et al. Characterization of biochemically atypical Vibrio cholerae strains and designation of a new pathogenic species, Vibrio mimicus. J Clin Microbiol 1981; 14:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/10\">",
"      Hasan NA, Grim CJ, Haley BJ, et al. Comparative genomics of clinical and environmental Vibrio mimicus. Proc Natl Acad Sci U S A 2010; 107:21134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/11\">",
"      Chowdhury MA, Aziz KM, Kay BA, Rahim Z. Toxin production by Vibrio mimicus strains isolated from human and environmental sources in Bangladesh. J Clin Microbiol 1987; 25:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/12\">",
"      Okada N, Matsuda S, Matsuyama J, et al. Presence of genes for type III secretion system 2 in Vibrio mimicus strains. BMC Microbiol 2010; 10:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/13\">",
"      Elhadi N, Radu S, Chen CH, Nishibuchi M. Prevalence of potentially pathogenic Vibrio species in the seafood marketed in Malaysia. J Food Prot 2004; 67:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/14\">",
"      Maugeri TL, Caccamo D, Gugliandolo C. Potentially pathogenic vibrios in brackish waters and mussels. J Appl Microbiol 2000; 89:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/15\">",
"      Shandera WX, Johnston JM, Davis BR, Blake PA. Disease from infection with Vibrio mimicus, a newly recognized Vibrio species. Clinical characteristics and edipemiology. Ann Intern Med 1983; 99:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Vibrio mimicus infection from consuming crayfish --- Spokane, Washington, June 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/17\">",
"      Chitov T, Kirikaew P, Yungyune P, et al. An incidence of large foodborne outbreak associated with Vibrio mimicus. Eur J Clin Microbiol Infect Dis 2009; 28:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/18\">",
"      Campos E, Bola&ntilde;os H, Acu&ntilde;a MT, et al. Vibrio mimicus diarrhea following ingestion of raw turtle eggs. Appl Environ Microbiol 1996; 62:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/19\">",
"      Lee JV, Shread P, Furniss AL, Bryant TN. Taxonomy and description of Vibrio fluvialis sp. nov. (synonym group F vibrios, group EF6). J Appl Bacteriol 1981; 50:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/20\">",
"      Chakraborty R, Chakraborty S, De K, et al. Cytotoxic and cell vacuolating activity of Vibrio fluvialis isolated from paediatric patients with diarrhoea. J Med Microbiol 2005; 54:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/21\">",
"      Lockwood DE, Kreger AS, Richardson SH. Detection of toxins produced by vibrio fluvialis. Infect Immun 1982; 35:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/22\">",
"      Seidler RJ, Allen DA, Colwell RR, et al. Biochemical characteristics and virulence of environmental group F bacteria isolated in the United States. Appl Environ Microbiol 1980; 40:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/23\">",
"      Huq MI, Alam AK, Brenner DJ, Morris GK. Isolation of Vibrio-like group, EF-6, from patients with diarrhea. J Clin Microbiol 1980; 11:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/24\">",
"      Y&uuml;cel N, Balci S. Prevalence of listeria, Aeromonas, and Vibrio species in fish used for human consumption in Turkey. J Food Prot 2010; 73:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/25\">",
"      Tall BD, Fall S, Pereira MR, et al. Characterization of Vibrio fluvialis-like strains implicated in limp lobster disease. Appl Environ Microbiol 2003; 69:7435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/26\">",
"      Bhattacharjee S, Bhattacharjee S, Bal B, et al. Is Vibrio fluvialis emerging as a pathogen with epidemic potential in coastal region of eastern India following cyclone Aila? J Health Popul Nutr 2010; 28:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/27\">",
"      Lesmana M, Subekti DS, Tjaniadi P, et al. Spectrum of vibrio species associated with acute diarrhea in North Jakarta, Indonesia. Diagn Microbiol Infect Dis 2002; 43:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/28\">",
"      Lux TM, Lee R, Love J. Complete genome sequence of a free-living Vibrio furnissii sp. nov. strain (NCTC 11218). J Bacteriol 2011; 193:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/29\">",
"      Matt&eacute; GR, Matt&eacute; MH, Sato MI, et al. Potentially pathogenic vibrios associated with mussels from a tropical region on the Atlantic coast of Brazil. J Appl Bacteriol 1994; 77:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/30\">",
"      Centers for Disease Control. Follow-up of outbreak of gastroenteritis during a tour of the orient &ndash; Alaska. MMWR Morbid Mortal Wkly Rep 1969; 18:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/31\">",
"      Dalsgaard A, Glerup P, H&oslash;ybye LL, et al. Vibrio furnissii isolated from humans in Peru: a possible human pathogen? Epidemiol Infect 1997; 119:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/32\">",
"      Derber C, Coudron P, Tarr C, et al. Vibrio furnissii: an unusual cause of bacteremia and skin lesions after ingestion of seafood. J Clin Microbiol 2011; 49:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/33\">",
"      Nordstrom JL, Vickery MC, Blackstone GM, et al. Development of a multiplex real-time PCR assay with an internal amplification control for the detection of total and pathogenic Vibrio parahaemolyticus bacteria in oysters. Appl Environ Microbiol 2007; 73:5840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/34\">",
"      Myatt DC, Davis GH. Isolation of medically significant Vibrio species from riverine sources in south east Queensland. Microbios 1989; 60:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/35\">",
"      Cavallo RA, Stabili L. Presence of vibrios in seawater and Mytilus galloprovincialis (Lam.) from the Mar Piccolo of Taranto (Ionian Sea). Water Res 2002; 36:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/36\">",
"      Edouard S, Daumas A, Branger S, et al. Grimontia hollisae, a potential agent of gastroenteritis and bacteraemia in the Mediterranean area. Eur J Clin Microbiol Infect Dis 2009; 28:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/37\">",
"      Morris JG Jr, Miller HG, Wilson R, et al. Illness caused by Vibrio damsela and Vibrio hollisae. Lancet 1982; 1:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/38\">",
"      Hinestrosa F, Madeira RG, Bourbeau PP. Severe gastroenteritis and hypovolemic shock caused by Grimontia (Vibrio) hollisae infection. J Clin Microbiol 2007; 45:3462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/39\">",
"      Yishan L, Jiaming F, Zaohe W, Jichang J. Genotype analysis of collagenase gene by PCR-SSCP in Vibrio alginolyticus and its association with virulence to marine fish. Curr Microbiol 2011; 62:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/40\">",
"      Zhao Z, Chen C, Hu CQ, et al. The type III secretion system of Vibrio alginolyticus induces rapid apoptosis, cell rounding and osmotic lysis of fish cells. Microbiology 2010; 156:2864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/41\">",
"      Masini L, De Grandis G, Principi F, et al. Research and characterization of pathogenic vibrios from bathing water along the Conero Riviera (Central Italy). Water Res 2007; 41:4031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/42\">",
"      Schets FM, van den Berg HH, Demeulmeester AA, et al. Vibrio alginolyticus infections in the Netherlands after swimming in the North Sea. Euro Surveill 2006; 11:E061109.3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/43\">",
"      Schets FM, van den Berg HH, Rutjes SA, de Roda Husman AM. Pathogenic Vibrio species in dutch shellfish destined for direct human consumption. J Food Prot 2010; 73:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/44\">",
"      Blake PA, Weaver RE, Hollis DG. Diseases of humans (other than cholera) caused by vibrios. Annu Rev Microbiol 1980; 34:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/45\">",
"      Bonner JR, Coker AS, Berryman CR, Pollock HM. Spectrum of Vibrio infections in a Gulf Coast community. Ann Intern Med 1983; 99:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/46\">",
"      Prociv P. Vibrio alginolyticus in Western Australia. Med J Aust 1978; 2:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/47\">",
"      Love M, Teebken-Fisher D, Hose JE, et al. Vibrio damsela, a Marine Bacterium, Causes Skin Ulcers on the Damselfish Chromis punctipinnis. Science 1981; 214:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/48\">",
"      Kreger AS. Cytolytic activity and virulence of Vibrio damsela. Infect Immun 1984; 44:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/504/abstract/49\">",
"      Goodell KH, Jordan MR, Graham R, et al. Rapidly advancing necrotizing fasciitis caused by Photobacterium (Vibrio) damsela: a hyperaggressive variant. Crit Care Med 2004; 32:278.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16535 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_504=[""].join("\n");
var outline_f0_31_504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22319378\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H631646146\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10851452\">",
"      EPIDEMIOLOGY COMMON TO VIBRIO SPECIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H631646153\">",
"      SPECIES THAT PRIMARILY CAUSE DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631646161\">",
"      V. mimicus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631646168\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631646175\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631646204\">",
"      V. fluvialis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631646211\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H631646218\">",
"      - Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631646247\">",
"      V. furnissii",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631646262\">",
"      Grimontia (Vibrio) hollisae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H631646285\">",
"      SPECIES THAT PRIMARILY CAUSE WOUND INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631646293\">",
"      V. alginolyticus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H631646308\">",
"      Photobacterium (Vibrio) damsela",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10851583\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22319510\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22319517\">",
"      Diarrheal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22319573\">",
"      Wound infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22319378\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/16535\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16535|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/60/5070\" title=\"figure 1\">",
"      Vibrio cases by month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/16535|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/15/3325\" title=\"table 1\">",
"      Vibrio isolates in the US over five years",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18502?source=related_link\">",
"      Infections due to non-O1/O139 Vibrio cholerae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36073?source=related_link\">",
"      Overview of Vibrio cholerae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27878?source=related_link\">",
"      Vibrio parahaemolyticus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_31_505="Treatment of central diabetes insipidus";
var content_f0_31_505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of central diabetes insipidus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/505/contributors\">",
"     Daniel G Bichet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/505/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/505/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/505/contributors\">",
"     Michael Emmett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/505/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/31/505/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/505/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/31/505/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/31/505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major symptoms of central diabetes insipidus (DI) are polyuria, nocturia, and polydipsia due to the concentrating defect. Treatment of this disorder is primarily aimed at decreasing the urine output, usually by increasing the activity of antidiuretic hormone (ADH, also called arginine vasopressin or AVP).",
"   </p>",
"   <p>",
"    Replacement of previous and ongoing fluid losses is also important. Most patients with central DI have a normal or only mildly elevated plasma sodium concentration because concurrent stimulation of thirst minimizes the degree of net water loss. However, hypernatremia can occur if thirst is impaired or the patient has no access to water [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/1\">",
"     1",
"    </a>",
"    ]. Correction of the hypernatremia requires repair of this free water deficit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=see_link\">",
"     \"Treatment of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of central DI will be reviewed here. The causes of this disorder and the approach to the patient with polyuria are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H144709921\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main options for the treatment of polyuria in patients with central DI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      , which is an ADH analog and is the preferred drug in almost all patients.",
"     </li>",
"     <li>",
"      Other drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , thiazide diuretics, and nonsteroidal antiinflammatory drugs.",
"     </li>",
"     <li>",
"      A low solute (mostly low sodium, low protein) diet. In normal individuals, the urine output is primarily determined by fluid intake, a relationship that is mediated by changes in the release of antidiuretic hormone (ADH). When the urine osmolality is fixed, as in untreated DI, the urine output is determined by the intake and subsequent urinary excretion of solutes (mostly sodium salts and urea), which has been called the renal solute load. As an example, at a fixed urine osmolality of 100",
"      <span class=\"nowrap\">",
"       mosmol/kg,",
"      </span>",
"      the urine output will be 6",
"      <span class=\"nowrap\">",
"       L/day",
"      </span>",
"      if urinary solute excretion is 600",
"      <span class=\"nowrap\">",
"       mosmol/day",
"      </span>",
"      and 3 L if urinary solute excretion is 300",
"      <span class=\"nowrap\">",
"       mosmol/day",
"      </span>",
"      on a low sodium, reduced protein diet. A low solute diet can be combined with a thiazide diuretic. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Low solute diet and thiazide diuretics'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of therapy varies with the severity of the polyuria. Patients with partial DI and mild to moderate polyuria and nocturia may be adequately controlled with a low solute diet (if acceptable to the patient) and, if necessary, a thiazide diuretic. Although these modalities also reduce the urine output in patients with marked polyuria and nocturia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy is usually required for symptom control. Desmopressin can also be used in patients with less severe DI who do not want to comply with a low solute diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216816629\">",
"    <span class=\"h1\">",
"     THERAPEUTIC GOAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only symptoms of DI are polyuria, nocturia, and thirst (unless the patient has a hypothalamic lesion causing hypodipsia). Thirst is essential so that the excess urinary water losses can be replaced. Patients without an intact thirst mechanism can develop severe hypernatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and evaluation of hypernatremia\", section on 'Hypothalamic lesions affecting thirst or osmoreceptor function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial aim of therapy is to reduce nocturia, thereby providing adequate sleep, most often by the administration at bedtime of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , which is the",
"    <strong>",
"     preferred therapy",
"    </strong>",
"    for central DI. Once this is achieved, one aims for",
"    <strong>",
"     partial",
"    </strong>",
"    control of the diuresis during the day, since complete control can lead to retention of water and hyponatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216816636\">",
"    <span class=\"h2\">",
"     Risk of hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water retention leading to the development of hyponatremia is a potential risk in patients with central DI who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    or other therapies that increase the response to or secretion of ADH (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ). Once desmopressin is given, the patient has nonsuppressible ADH activity and may be unable to excrete ingested water normally, possibly leading to hyponatremia, as occurs in patients with the syndrome of inappropriate ADH secretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Pathogenesis of hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although thirst will be suppressed by effective therapy, much of the fluid intake during the day is not driven by thirst (eg, coffee with breakfast, soda with lunch and dinner). In addition, previously untreated patients may have become accustomed to drinking large amounts of fluids and may continue to do so for a short period after the initiation of effective therapy to control polyuria, possibly resulting in the development of hyponatremia. Thus, we suggest measuring the serum sodium one to two days after the initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy and, if the initial measurement is normal, repeating the measurement at four days.",
"   </p>",
"   <p>",
"    Once a stable dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is achieved, annual or biannual monitoring of the serum sodium may be performed. If a patient treated with a stable dose of desmopressin begins experiencing increased urinary frequency or nocturia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the serum sodium is elevated, a 24-hour urine should be collected to ascertain whether the patient is polyuric.",
"   </p>",
"   <p>",
"    Preventing water retention is more difficult in infants and young children and more frequent monitoring of the serum sodium concentration is recommended. (See",
"    <a class=\"local\" href=\"#H45645699\">",
"     'Monitoring of serum sodium'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216816726\">",
"    <span class=\"h3\">",
"     Dosing to prevent hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of hyponatremia, patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    should be educated about the symptoms that may be induced by hyponatremia. These include nausea, vomiting, headache, lethargy, and, if severe, seizures and coma. Patients should be instructed to call the physician at the first sign of such manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"     \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    dosing is an empiric process. Hyponatremia can usually be avoided by giving the",
"    <strong>",
"     minimum",
"    </strong>",
"    desmopressin dose that is required to control the polyuria. The initial aim of therapy is to reduce nocturia, thereby permitting adequate sleep. Thus, the first dose (0.1 or 0.2 mg tablet or 5 to 10 microg of the nasal spray) is typically given at bedtime. The size of and necessity for a daytime dose is determined by the effectiveness of the evening dose. If, for example, polyuria does not recur until noon, then one-half the evening dose may be sufficient at that time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H216816692\">",
"    <span class=\"h2\">",
"     Course of DI and duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of central DI varies with the cause. As examples, DI is permanent in idiopathic disease, most often transient following neurosurgery (usually transsphenoidal) or trauma, and may be reversible with appropriate therapy in patients with infiltrative diseases. The supportive data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    therapy should be continued for as long as the patient has symptomatic central DI. As mentioned above, the goal of therapy is control of nocturia and partial control of polyuria during the day since more aggressive therapy can promote the development of hyponatremia. The DI induced by neurosurgery or trauma is often transient. Thus, such patients should be questioned carefully at each visit about the degree of polyuria. If the polyuria is said to be less pronounced or to have ceased, the desmopressin dose can be gradually tapered and eventually withdrawn if polyuria does not recur. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DESMOPRESSIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the primary problem in central DI is deficient secretion of ADH, control of the polyuria can be achieved by hormone replacement. In the past, this was achieved by intramuscular injections of vasopressin (Pitressin) tannate in oil, which is no longer available. This preparation had two problems: the requirement for intramuscular administration; and the occasional development of anti-vasopressin antibodies with a secondary increase in urine output that appears to be ADH-resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intramuscular vasopressin has been replaced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    (dDAVP), a two-amino acid substitute of ADH that has potent antidiuretic but no vasopressor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H144709866\">",
"    <span class=\"h2\">",
"     Preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    comes in liquid form that is usually administered intranasally, in an oral tablet form, and a parenteral formulation. The intranasal preparation can be blown into the nose by the patient with a curved, dose-calibrated small plastic tube or delivered with a nasal spray. An initial dose of 5 microg at bedtime can be titrated upward in 5 microg increments depending upon the response of the nocturia and then additional daytime doses added. The daily maintenance dose is about 5 to 20 microg once or twice a day.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    metered spray bottle is currently used more commonly than the rhinal tube because of greater convenience of administration. Although flexibility is more limited with the metered spray bottle because the minimum dose is 10 microg, this does not represent a problem for most patients. The usual daily maintenance dose is 10 to 20 microg intranasally once or twice a day. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     \"Desmopressin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An oral tablet preparation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is also available [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/4\">",
"     4",
"    </a>",
"    ]. The absorption of desmopressin in normal persons is decreased by 40 to 50 percent when taken with meals [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/5\">",
"     5",
"    </a>",
"    ]. This usually has little effect on the antidiuretic action but administering the drug in the fasting state may be tried if there is a poor response to the usual doses taken with meals.",
"   </p>",
"   <p>",
"    The oral form has about one-tenth to one-twentieth the potency of the nasal form because only about five percent is absorbed from the gut. Thus, a 0.1 mg tablet is the equivalent of 2.5 to 5 microg of the nasal spray. However, because the oral dose cannot be precisely predicted from a previous nasal dose, transfer of patients from nasal insufflation to oral therapy usually requires some dosage retitration.",
"   </p>",
"   <p>",
"    The initial dose of the tablet form is 0.05 mg (one-half a 0.1 mg tablet) at bedtime with titration as with the liquid form. The usual daily maintenance dose ranges from 0.1 mg to 0.8 mg in divided doses but may be as high as 1.2",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    There are few long-term data on the use of the tablet form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    . In one study, eight children with central DI were treated and followed for up to 3.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/6\">",
"     6",
"    </a>",
"    ]. There was no attenuation of the antidiuretic effect and no side effects or antibody formation were noted. In another report, ten adults had satisfactory maintenance of the antidiuretic effect over one year with doses of 0.3 to 0.6",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    given in two to three doses per day; doses larger than 0.2 mg had no greater effect, eg, 0.4 versus 0.2 mg, but probably lasted longer [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although patients generally prefer the oral preparation because of ease of administration, not all patients have an adequate response. As a result, we recommend starting with the intranasal preparation; this ensures that the patient understands what constitutes a good antidiuretic response prior to performing a trial of oral therapy.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    cannot be administered intranasally or orally, it can be given subcutaneously. A usual antidiuretic dose is 1 microg administered subcutaneously every 12 hours. Some patients do not respond well to subcutaneous desmopressin due to inadequate absorption. Such patients can be treated with 2 microg of desmopressin acetate given intravenously over two minutes; the duration of action, as judged by increased urine osmolality, will be 12 hours or more [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     Desmopressin",
"    </a>",
"    is",
"    <strong>",
"     safe",
"    </strong>",
"    during pregnancy for both the mother and the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OTHER DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the vast majority of patients with central DI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is readily available, safe, and effective. Other drugs that can be used are thiazide diuretics, which act independent of ADH, and, in patients with partial central DI (ie, there is some circulating vasopressin), drugs that increase ADH release or enhance ADH effect on the kidney such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , clofibrate, and nonsteroidal antiinflammatory drugs. These drugs are associated with more side effects than desmopressin and are generally less effective, lowering the urine output by 25 to 60 percent, although a greater effect may be seen with thiazide diuretics.",
"   </p>",
"   <p>",
"    Thiazide diuretics and nonsteroidal antiinflammatory drugs also constitute the only effective therapy for nephrogenic DI, which is characterized by ADH resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link\">",
"     \"Treatment of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chlorpropamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     Chlorpropamide",
"    </a>",
"    , an oral hypoglycemic agent, is the most commonly used antidiuretic drug after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]; it appears to act by enhancing the renal response to ADH or to desmopressin. Studies in animals suggest that this response may be mediated by enhanced sodium chloride reabsorption in the thick ascending limb (thereby increasing the degree of medullary hypertonicity)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by increased collecting tubule permeability to water; how these changes occur is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The usual dose is 125 to 250 mg, once or twice a day; higher doses may produce a somewhat greater response but also increase the risk of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/12\">",
"     12",
"    </a>",
"    ]. Chlorpropamide can lower the urine output by as much as 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Carbamazepine or clofibrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    (used to treat seizures and tic douloureux) in a dose of 100 to 300 mg twice daily and clofibrate (used in the treatment of hyperlipidemia) in a dose of 500 mg every six hours can ameliorate the polyuria in partial central DI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ]. Carbamazepine appears to enhance the response to ADH [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/17\">",
"     17",
"    </a>",
"    ], whereas clofibrate may increase ADH release [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/16\">",
"     16",
"    </a>",
"    ]. Carbamazepine can lower the urine output by as much as 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/15\">",
"     15",
"    </a>",
"    ] and clofibrate by a mean of 50 percent but is not as predictably effective as carbamazepine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The induction of mild volume depletion with a low sodium diet plus a thiazide diuretic (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , 25 mg once or twice daily or its equivalent) is a first-line therapy in nephrogenic DI and is also effective in central DI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As little as a 1 to 1.5 kg weight loss can reduce the urine output by more than 50 percent, from 10",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    to below 3.5",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in one study of patients with nephrogenic DI [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of nephrogenic diabetes insipidus\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of thiazide diuretics is presumably mediated by a hypovolemia-induced increase in proximal sodium and water reabsorption, thereby diminishing water delivery to the ADH-sensitive sites in the collecting tubules and reducing the urine output. The thiazide effect is additive to that of the other modalities. Thiazides also tend to modestly raise the plasma glucose concentration, thereby decreasing the likelihood of hypoglycemia in patients who are also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     chlorpropamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Chlorpropamide'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) increase urinary concentrating ability by inhibiting the renal synthesis of prostaglandins, which are ADH antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/21\">",
"     21",
"    </a>",
"    ]. In normal subjects, pretreatment with an NSAID increases the antidiuretic effect of a submaximal dose of ADH, amplifying the increase in urine osmolality by more than 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/22\">",
"     22",
"    </a>",
"    ]. The net effect in patients with DI may be a 25 to 50 percent reduction in urine output [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], a response that is partially additive to that of a thiazide diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all NSAIDs are equally effective in a given patient. As an example, some patients have a good response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    but derive little if any benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to removing the underlying causes, if possible, children with DI are treated with a low solute diet to reduce urinary solute excretion and therefore the urine output, and pharmacologic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a thiazide diuretic.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"     Chlorpropamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and clofibrate should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children, since limited data suggest that they are less effective than desmopressin and have significant adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"     \"Clinical manifestations and causes of central diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of central DI varies with the age of the child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Older children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older children with an intact thirst mechanism are able to regulate their fluid balance, and independently access free water and monitor their urine output. As a result they can be treated in a manner similar to adults with oral or intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The dosing of both oral and intranasal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    in children older than 12 years of age is the same as in adults. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Desmopressin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial oral dose is 0.05 mg at bedtime and is titrated to a desired response to an upper daily limit of 1.2 mg (divided two to three times a day).",
"     </li>",
"     <li>",
"      The initial intranasal dose begins at 5 microg at bedtime and is titrated to a desired response to an upper daily dose of 40 microg (divided two times a day).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children younger than 12 years of age, the same initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    dose is used, but the upper daily limit of the oral medication is 0.8 mg (divided two to three times a day), and the upper daily limit of the intranasal preparation is 30 microg (divided two times a day).",
"   </p>",
"   <p>",
"    Thiazide diuretic therapy and a low sodium diet are used to induce mild volume depletion, which will reduce the urine output. The dose of the thiazide is weight-based. Adolescents can be treated with same dose used in adults (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , 25 mg once or twice daily or its equivalent). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Thiazide diuretics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Infants and small children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of infants and small children with central DI is challenging for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral or intranasal administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      is difficult to administer accurately in infants and small children; thus, when used, desmopressin is often given subcutaneously. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Subcutaneous desmopressin therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Infants and small children are unable to both access fluids and articulate thirst to care providers.",
"     </li>",
"     <li>",
"      It is often challenging to ascertain the volume of urine output in children who are not toilet trained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants receive all or most of their nutrition in liquid form. As a result, they are at risk for hyponatremia when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy because of their high obligatory oral fluid requirement (150",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day). Thus, frequent measurement of the serum sodium concentration is essential at the initiation of therapy and one to two days after any change in desmopressin dose.",
"   </p>",
"   <p>",
"    Two approaches are used to treat infants and small children: a low solute diet plus thiazide diuretics, which is generally preferred; and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/18\">",
"     18",
"    </a>",
"    ]. With both of these approaches, families need to be taught to monitor urine output (frequency and number of wet diapers) and identify signs of hyponatremia or hypernatremia, which are often nonspecific and include irritability and lethargy. When oral intake is reduced, as occurs with intercurrent illness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid losses are increased, as occurs with vomiting and diarrhea, vigilance should be increased to detect signs of hypovolemia (ie, dry mucous membranes, decreased urine output, sunken fontanelle, and decreased weight). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Clinical assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Low solute diet and thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low solute diet (low salt and low protein [which is metabolized to urea]) and a thiazide diuretic can be used to reduce the urine output and therefore thirst in infants and toddlers with central DI who are not treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    . When the urine osmolality is fixed, as in central DI without desmopressin therapy, the urine output is determined by the intake and subsequent excretion of solutes such as sodium salts and urea, which has been called the renal solute load. (See",
"    <a class=\"local\" href=\"#H144709921\">",
"     'Choice of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For infants who are dependent upon a milk diet, human milk is preferred because of its proven nutritional and immunologic benefits and a lower solute load compared with Similac PM",
"    <span class=\"nowrap\">",
"     60/40",
"    </span>",
"    (low solute cow milk-based formula), regular cow milk-based formula, soy-based formula, and cow's milk (75, 92, 110, 126, and 235",
"    <span class=\"nowrap\">",
"     mosmol/L,",
"    </span>",
"    respectively). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of a low solute diet can be illustrated by the following example. Suppose an infant with a daily intake of 750 mL of human milk has a maximum urine osmolality of 100",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    This quantity of human milk provides 56 milliosmoles of solute per day (0.75 L x 75",
"    <span class=\"nowrap\">",
"     milliosmoles/L)",
"    </span>",
"    so that the daily urine volume would be 0.56 L (56 milliosmoles per",
"    <span class=\"nowrap\">",
"     day/100",
"    </span>",
"    <span class=\"nowrap\">",
"     milliosmoles/L).",
"    </span>",
"    Changing to a regular cow milk-based formula would increase the renal solute load to 83",
"    <span class=\"nowrap\">",
"     mosmol/day",
"    </span>",
"    (0.75 L x 110",
"    <span class=\"nowrap\">",
"     milliosmoles/L)",
"    </span>",
"    and the daily urine volume would increase by 0.28 L to 0.84 L (ie, from 560 to 840",
"    <span class=\"nowrap\">",
"     mL/day).",
"    </span>",
"   </p>",
"   <p>",
"    Thiazide therapy is typically given with the low solute diet to induce mild volume depletion, which will further reduce the urine volume. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    is commonly used in infants up to six months of age at a dose of 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in two doses, maximum dose: 37.5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The dose in older infants and small children is 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day (divided in two doses).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Subcutaneous desmopressin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and small children treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy are at considerable risk for water intoxication and hyponatremia as they may not be able to eliminate the daily water load. This risk may be increased because accurate and consistent dosing of oral and intranasal desmopressin is difficult due to variable absorption and the challenge of administering these preparations to infants and small children.",
"   </p>",
"   <p>",
"    As a result, if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    is to be used, several experts prefer subcutaneous desmopressin, which is more reliably administered to infants and small children. The starting dose is 0.01",
"    <span class=\"nowrap\">",
"     microg/day,",
"    </span>",
"    which is titrated to a desired response (eg, reduction in urine output, while maintaining a normal serum sodium). The reported range of dosing is 0.02 to 0.08",
"    <span class=\"nowrap\">",
"     microg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/18,27\">",
"     18,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45645699\">",
"    <span class=\"h3\">",
"     Monitoring of serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and small children differ from older children and adults since all or almost all of their calories are consumed as liquids, not as solids. As a result, monitoring of the serum sodium concentration and body weight is important to detect hypernatremia due to water loss with a low solute diet and thiazide diuretic and to detect hyponatremia due to water retention resulting from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    We suggest the following approach in infants and small children treated with a",
"    <strong>",
"     low solute diet and a thiazide diuretic",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum sodium should initially be measured at least daily.",
"     </li>",
"     <li>",
"      If the serum sodium is normal at one to two days, we suggest repeat measurement at three to four days and then at every patient visit. If the serum sodium is elevated, fluid intake should be increased and the serum sodium measured serially until it is stable in the normal range.",
"     </li>",
"     <li>",
"      The serum sodium should be measured immediately whenever there is an alteration in clinical status, particularly when an intercurrent illness impairs fluid intake",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increases fluid losses, both of which will tend to raise the serum sodium.",
"     </li>",
"     <li>",
"      Infants should be weighed frequently since weight loss or less than expected weight gain could be indicative of water loss and hypernatremia in between usual measurements of the serum sodium concentration. Normal healthy infants lose up to 10 percent of their birth weight during the first week of life, a loss that is regained by two weeks of age. Thereafter, a healthy infant should gain weight at a rate of approximately 30",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in the first three months, 20",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      from three to six months, 15",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      from six to nine months, 12",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      from nine to twelve months, and 8",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      from one to three years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=see_link&amp;anchor=H6#H6\">",
"       \"Normal growth patterns in infants and prepubertal children\", section on 'Weight gain'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the following approach in infants and small children treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serum sodium should be measured at least daily after the initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      as well as after any dose adjustment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/18,27\">",
"       18,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If the serum sodium is normal at one to two days, we suggest repeat measurement at three to four days since some young children have a later onset of hyponatremia.",
"     </li>",
"     <li>",
"      If any serum sodium measurement is below normal, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      dose should be reduced and the serum sodium measured one to two days later.",
"     </li>",
"     <li>",
"      In children on a stable dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      , the serum sodium should be measured every one to two years.",
"     </li>",
"     <li>",
"      Infants should be weighed frequently since more than expected gains, as defined in the preceding paragraph, could reflect water retention and hyponatremia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyponatremia is less likely to occur in older children and adults treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    since, as noted above, the goal of therapy is only partial control of the polyuria during the day, which minimizes the risk of water retention. (See",
"    <a class=\"local\" href=\"#H216816726\">",
"     'Dosing to prevent hyponatremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROBLEM WITH INTRAVENOUS FLUID REPLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;When thirst is intact and there is free access to water, most patients with central DI can replace their water losses orally. Patients who are unable to drink water must be treated with intravenous dextrose and water (because intravenous sterile water without dextrose causes hemolysis).",
"   </p>",
"   <p>",
"    There is a potential complication if this is performed before the polyuria is corrected by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    . In adults, the intravenous administration of dextrose and water at more than 1000",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    delivers glucose at a rate that exceeds endogenous metabolic capacity for glucose even in patients without diabetes mellitus, possibly leading to severe and symptomatic hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/31/505/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, intravenous rates of fluid replacement with dextrose in water should be limited to a maximum of 500 to 750",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    and serum glucose levels should be monitored. Avoiding excess dextrose administration can be more readily achieved by administering desmopressin to reduce the urine flow rate.",
"   </p>",
"   <p>",
"    This sequence can also occur when patients with central DI and impaired consciousness present with polyuria and hypernatremia of unknown cause. One way to avoid this is to ensure that patients with central DI have a Medic Alert bracelet so that treating physicians will be aware of the need to administer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    in such instances.",
"   </p>",
"   <p>",
"    The development of hyperglycemia for any reason may have an additional effect that can be confusing clinically. Marked glucosuria can lead to an osmotic diuresis that is",
"    <strong>",
"     ADH-resistant",
"    </strong>",
"    . In this setting, the urine osmolality is typically similar to the plasma osmolality and polyuria is driven by the solute load. The administration of insulin to correct the hyperglycemia will restore responsiveness to ADH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=see_link\">",
"       \"Patient information: Diabetes insipidus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27520276\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major symptoms of central diabetes insipidus (DI) are polyuria, nocturia, and polydipsia. Most patients have a normal or only mildly elevated plasma sodium concentration because concurrent stimulation of thirst minimizes the degree of net water loss. Treatment of this disorder is aimed at decreasing the urine output. (See",
"      <a class=\"local\" href=\"#H216816629\">",
"       'Therapeutic goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three major therapeutic options: a low solute (sodium and protein) diet;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (dDAVP), an ADH analog; and other drugs, including thiazide diuretics. The choice of therapy varies with the severity of the polyuria. Patients with partial DI and mild to moderate polyuria and nocturia may be adequately controlled with a low solute diet (if acceptable to the patient) and, if necessary, a thiazide diuretic. Although these modalities also reduce the urine output in patients with marked polyuria and nocturia, desmopressin therapy is usually required for symptom control. Desmopressin can also be used in patients with less severe DI who do not want to comply with a low solute diet. (See",
"      <a class=\"local\" href=\"#H144709921\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial aim of therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      is to reduce nocturia, thereby permitting adequate sleep; after this is achieved, one aims for control of the diuresis during the day. The size of and necessity for a daytime dose is determined by the effectiveness of the evening dose. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Desmopressin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      can be administered intranasally, orally, subcutaneously, or intravenously. The intranasal preparation should be used initially as not all patients respond to oral therapy. (See",
"      <a class=\"local\" href=\"#H144709866\">",
"       'Preparations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For the intranasal preparation, an initial dose of 5 microg at bedtime can be titrated upward in 5 microg increments depending upon the response of the nocturia. The usual daily maintenance dose is 5 to 20 microg once or twice a day.",
"     </li>",
"     <li>",
"      For the oral preparation, the initial dose is 0.05 mg (one-half a 0.1 mg tablet) at bedtime with subsequent titration as with the intranasal preparation. The usual daily maintenance dose ranges from 0.1 mg to 0.8 mg in divided doses but may be as high as 1.2",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      For the subcutaneous preparation, the usual dose is 1 microg every 12 hours.",
"     </li>",
"     <li>",
"      For intravenous administration (in patients who do not have an adequate response to the subcutaneous preparation), 2 microg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      acetate may be given over two minutes; the duration of action is 12 hours or more.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      can lead to water retention and hyponatremia if the urine is concentrated for most of the day. This can usually be avoided by giving the minimum required dose to control the polyuria and not administering another dose until the patient has had a period of brisk diuresis, indicating that the effect of the previous dose of desmopressin had waned. The serum sodium concentration should be checked at 24 hours after the initiation of desmopressin therapy and patients educated about the symptoms that may be induced by hyponatremia. These include nausea, vomiting, headache, lethargy, and, if severe, seizures and coma. Patients should be instructed to call the physician if such manifestations occur. (See",
"      <a class=\"local\" href=\"#H216816636\">",
"       'Risk of hyponatremia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link&amp;anchor=H2#H2\">",
"       \"Manifestations of hyponatremia and hypernatremia\", section on 'Hyponatremia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       Desmopressin",
"      </a>",
"      therapy should be continued for as long as the patient has central DI. The duration of central DI varies: DI is permanent in idiopathic disease, improves in some elderly patients with familial disease, may be transient following neurosurgery (usually transsphenoidal), and may be reversible with appropriate therapy in patients with infiltrative diseases. (See",
"      <a class=\"local\" href=\"#H216816692\">",
"       'Course of DI and duration of therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=see_link\">",
"       \"Clinical manifestations and causes of central diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other drugs that may decrease diuresis include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/0/6151?source=see_link\">",
"       chlorpropamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      and clofibrate, nonsteroidal antiinflammatory drug (NSAID) and thiazide diuretics. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of children with central DI varies with the age of the child. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Older children (more than 12 years of age) can be treated in a similar manner as adults with oral or intranasal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Older children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children younger than 12 years of age may be given the same initial",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      dose, but the upper daily limit of the oral medication is 0.8 mg (divided two to three times a day), and the upper daily limit of the intranasal preparation is 30 microg (divided two times a day). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Older children'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Thiazide diuretic therapy and a low sodium diet are used to induce mild volume depletion, which will reduce the urine output. The dose of the thiazide is weight-based. Adolescents can be treated with same dose used in adults (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      , 25 mg once or twice daily or its equivalent). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Older children'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Infants and small children should be treated with a low solute diet (low salt and low protein) plus a thiazide diuretic. This will reduce the urine output and therefore thirst in infants and toddlers with central DI. For infants who are dependent upon a milk diet, human milk is preferred, if possible, because of its proven nutritional and immunologic benefits and lower solute load compared with formulae or cow&rsquo;s milk. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infants and small children'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Thiazide therapy is typically given with the low solute diet to induce mild volume depletion. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      is commonly used in infants up to six months of age at a dose of 2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in two doses, maximum dose: 37.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      The dose in older infants and small children is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (divided in two doses). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Low solute diet and thiazide diuretics'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      is required in infants and small children, subcutaneous desmopressin is the preferred preparation, since it is more reliably administered and its effect is more predictable than oral and intranasal desmopressin. The starting dose is 0.01",
"      <span class=\"nowrap\">",
"       microg/day,",
"      </span>",
"      which is titrated to a desired response (eg, reduction in urine output, while maintaining a normal serum sodium). The reported range of dosing is 0.02 to 0.08",
"      <span class=\"nowrap\">",
"       microg/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Subcutaneous desmopressin therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Infants and small children differ from older children and adults since all or almost all of their calories are consumed as liquids, not as solids. As a result, monitoring of the serum sodium concentration and body weight is important to detect hypernatremia due to water loss with a low solute diet and thiazide diuretic and to detect hyponatremia due to water retention resulting from desmopressin therapy. (See",
"      <a class=\"local\" href=\"#H45645699\">",
"       'Monitoring of serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/1\">",
"      Mavrakis AN, Tritos NA. Diabetes insipidus with deficient thirst: report of a patient and review of the literature. Am J Kidney Dis 2008; 51:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/2\">",
"      Vokes TJ, Gaskill MB, Robertson GL. Antibodies to vasopressin in patients with diabetes insipidus. Implications for diagnosis and therapy. Ann Intern Med 1988; 108:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/3\">",
"      Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985; 103:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/4\">",
"      Stenberg A, L&auml;ckgren G. Desmopressin tablets in the treatment of severe nocturnal enuresis in adolescents. Pediatrics 1994; 94:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/5\">",
"      Rittig S, Jensen AR, Jensen KT, Pedersen EB. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. Clin Endocrinol (Oxf) 1998; 48:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/6\">",
"      Fjellestad-Paulsen A, Laborde K, Kindermans C, Czernichow P. Water-balance hormones during long-term follow-up of oral dDAVP treatment in diabetes insipidus. Acta Paediatr 1993; 82:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/7\">",
"      Lam KS, Wat MS, Choi KL, et al. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus. Br J Clin Pharmacol 1996; 42:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/8\">",
"      Rembratt A, Graugaard-Jensen C, Senderovitz T, et al. Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55-70 years. Eur J Clin Pharmacol 2004; 60:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/9\">",
"      Vande Walle J, Stockner M, Raes A, N&oslash;rgaard JP. Desmopressin 30 years in clinical use: a safety review. Curr Drug Saf 2007; 2:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/10\">",
"      Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998; 53:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/11\">",
"      Webster B, Bain J. Antidiuretic effect and complications of chlorpropamide therapy in diabetes insipidus. J Clin Endocrinol Metab 1970; 30:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/12\">",
"      Rad&oacute; JP. Combination of carbamazepine and chlorpropamide in the treatment of \"hyporesponder\" pituitary diabetes insipidus. J Clin Endocrinol Metab 1974; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/13\">",
"      Welch WJ, Ott CE, Lorenz JN, Kotchen TA. Effects of chlorpropamide on loop of Henle function and plasma renin. Kidney Int 1986; 30:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/14\">",
"      Rocha AS, Ping WC, Kudo LH. Effect of chlorpropamide on water and urea transport in the inner medullary collecting duct. Kidney Int 1991; 39:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/15\">",
"      Wales JK. Treatment of diabetes insipidus with carbamazepine. Lancet 1975; 2:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/16\">",
"      Moses AM, Howanitz J, van Gemert M, Miller M. Clofibrate-induced antidiuresis. J Clin Invest 1973; 52:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/17\">",
"      Gold PW, Robertson GL, Ballenger JC, et al. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 1983; 57:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/18\">",
"      Rivkees SA, Dunbar N, Wilson TA. The management of central diabetes insipidus in infancy: desmopressin, low renal solute load formula, thiazide diuretics. J Pediatr Endocrinol Metab 2007; 20:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/19\">",
"      CRAWFORD JD, KENNEDY GC, HILL LE. Clinical results of treatment of diabetes insipidus with drugs of the chlorothiazide series. N Engl J Med 1960; 262:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/20\">",
"      Earley LE, Orloff J. THE MECHANISM OF ANTIDIURESIS ASSOCIATED WITH THE ADMINISTRATION OF HYDROCHLOROTHIAZIDE TO PATIENTS WITH VASOPRESSIN-RESISTANT DIABETES INSIPIDUS. J Clin Invest 1962; 41:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/21\">",
"      Stokes JB. Integrated actions of renal medullary prostaglandins in the control of water excretion. Am J Physiol 1981; 240:F471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/22\">",
"      Berl T, Raz A, Wald H, et al. Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 1977; 232:F529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/23\">",
"      Libber S, Harrison H, Spector D. Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors. J Pediatr 1986; 108:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/24\">",
"      Monnens L, Jonkman A, Thomas C. Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus. Clin Sci (Lond) 1984; 66:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/25\">",
"      Allen HM, Jackson RL, Winchester MD, et al. Indomethacin in the treatment of lithium-induced nephrogenic diabetes insipidus. Arch Intern Med 1989; 149:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/26\">",
"      Becker DJ, Foley TP Jr. 1-deamino-8-D-arginine vasopressin in the treatment of central diabetes insipidus in childhood. J Pediatr 1978; 92:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/27\">",
"      Blanco EJ, Lane AH, Aijaz N, et al. Use of subcutaneous DDAVP in infants with central diabetes insipidus. J Pediatr Endocrinol Metab 2006; 19:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/31/505/abstract/28\">",
"      Freidenberg GR, Kosnik EJ, Sotos JF. Hyperglycemic coma after suprasellar surgery. N Engl J Med 1980; 303:863.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2313 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_505=[""].join("\n");
var outline_f0_31_505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27520276\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H144709921\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H216816629\">",
"      THERAPEUTIC GOAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216816636\">",
"      Risk of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H216816726\">",
"      - Dosing to prevent hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H216816692\">",
"      Course of DI and duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DESMOPRESSIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H144709866\">",
"      Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OTHER DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chlorpropamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Carbamazepine or clofibrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Older children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Infants and small children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Low solute diet and thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Subcutaneous desmopressin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45645699\">",
"      - Monitoring of serum sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROBLEM WITH INTRAVENOUS FLUID REPLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27520276\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21048?source=related_link\">",
"      Clinical manifestations and causes of central diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=related_link\">",
"      Desmopressin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/55/43889?source=related_link\">",
"      Patient information: Diabetes insipidus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24393?source=related_link\">",
"      Treatment of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24071?source=related_link\">",
"      Treatment of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_31_506="Atazanavir: Drug information";
var content_f0_31_506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atazanavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=see_link\">",
"    see \"Atazanavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/7/7290?source=see_link\">",
"    see \"Atazanavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reyataz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Reyataz&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     <b>",
"      Treatment of HIV-1 infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-naive patients:",
"     </b>",
"     Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"     <b>",
"      or",
"     </b>",
"     atazanavir 400 mg once daily in patients unable to tolerate ritonavir.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended (with ritonavir) as a first-line therapy with tenofovir/emtricitabine in nonpregnant antiretroviral-naive patients (DHHS, 2013). Acceptable alternative regimens would be atazanavir plus lamivudine/zidovudine",
"     <b>",
"      or",
"     </b>",
"     atazanavir plus abacavir/lamivudine. Do not use tenofovir with unboosted atazanavir (DHHS, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-experienced patients:",
"     </b>",
"     Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Atazanavir without ritonavir is not recommended in antiretroviral-experienced patients with prior virologic failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pregnant patients:",
"     </b>",
"     Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Preferred regimen for pregnant patients who are antiretroviral-naive. Postpartum dosage adjustment not needed.  Observe patient for adverse events, especially within 2 months after delivery. Dose adjustments required for concomitant tenofovir",
"     <i>",
"      or",
"     </i>",
"     H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist use (insufficient information for dose adjustment if",
"     <i>",
"      both",
"     </i>",
"     tenofovir and an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist are used). Some experts recommend atazanavir 400 mg plus ritonavir 100 mg in all pregnant women during the second and third trimesters due to decreased plasma concentrations (DHHS [perinatal], 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustments for concomitant therapy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Coadministration with efavirenz:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-naive patients:",
"     </i>",
"     Atazanavir 400 mg plus ritonavir 100 mg given with efavirenz 600 mg (all once daily but administered at different times; atazanavir and ritonavir with food and efavirenz on an empty stomach).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced patients:",
"     </i>",
"     Concurrent use not recommended due to decreased atazanavir exposure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coadministration with didanosine buffered or enteric-coated formulations:",
"     </b>",
"     Administer atazanavir 2 hours before or 1 hour after didanosine buffered or enteric coated formulations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coadministration with H",
"      <sub>",
"       2",
"      </sub>",
"      antagonists:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-naive patients:",
"     </i>",
"     Atazanavir 300 mg plus ritonavir 100 mg given simultaneously with, or at least 10 hours after an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist equivalent dose of &le;80 mg famotidine/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Patients unable to tolerate ritonavir:",
"     </i>",
"     Atazanavir 400 mg once daily given at least 2 hours before or at least 10 hours after an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist equivalent daily dose of &le;40 mg famotidine (single dose &le;20 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced patients:",
"     </i>",
"     Atazanavir 300 mg plus ritonavir 100 mg given simultaneously with, or at least 10 hours after an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist equivalent dose of &le;40 mg famotidine/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced pregnant patients in the second or third trimester:",
"     </i>",
"     Atazanavir 400 mg plus ritonavir 100 mg simultaneously with, or at least 10 hours after an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist.",
"     <b>",
"      Note:",
"     </b>",
"     Insufficient information for dose adjustment if tenofovir",
"     <b>",
"      and",
"     </b>",
"     an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist are used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coadministration with proton pump inhibitors:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-naive patients:",
"     </i>",
"     Atazanavir 300 mg plus ritonavir 100 mg given 12 hours after a proton pump inhibitor equivalent dose of &le;20 mg omeprazole/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced patients:",
"     </i>",
"     Concurrent use not recommended. (",
"     <b>",
"      Note:",
"     </b>",
"     One study noted adequate serum concentrations when atazanavir 400 mg plus ritonavir 100 mg was given at the same time or 12 hours after omeprazole 20 mg.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Concurrent use is not recommended; however, if unavoidable, administer atazanavir 400 mg plus ritonavir 100 mg once daily with proton pump inhibitor equivalent dose of &le;20 mg omeprazole/day.",
"     <b>",
"      Note:",
"     </b>",
"     Manufacturer labeling does not specify patient population (antiretroviral-na&iuml;ve and/or experienced) to which dosing recommendation applies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Coadministration with tenofovir:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-naive patients:",
"     </i>",
"     Atazanavir 300 mg plus ritonavir 100 mg given with tenofovir 300 mg (all as a single daily dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced patients:",
"     </i>",
"     Atazanavir 300 mg plus ritonavir 100 mg given with tenofovir 300 mg (all as a single daily dose); if H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist coadministered (not to exceed equivalent daily dose of &le;40 mg famotidine), increase atazanavir to 400 mg (plus ritonavir 100 mg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced pregnant patients in the second or third trimester:",
"     </i>",
"     Atazanavir 400 mg plus ritonavir 100 mg.",
"     <b>",
"      Note:",
"     </b>",
"     Insufficient information for dose adjustment if tenofovir",
"     <b>",
"      and",
"     </b>",
"     an H",
"     <sub>",
"      2",
"     </sub>",
"     antagonist are used",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F554147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/7/7290?source=see_link\">",
"      see \"Atazanavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of HIV-1 infection:",
"     </b>",
"     Oral: Children 6 to &lt;18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Antiretroviral-naive patients:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Ritonavir-boosted atazanavir dosing regimen is preferred:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ritonavir-unboosted regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 6 years to &lt;13 years: Dose not established; use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;13 years and &lt;40 kg",
"     <b>",
"      who are not able to tolerate ritonavir",
"     </b>",
"     : No dosage recommendations provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;13 years and &ge;40 kg",
"     <b>",
"      who are not able to tolerate ritonavir",
"     </b>",
"     : Atazanavir 400 mg once daily (without ritonavir)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ritonavir-boosted regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     15 to &lt;20 kg: Atazanavir 150 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     20 to &lt;40 kg: Atazanavir 200 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &ge;40 kg: Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     100 mg ritonavir once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations (DHHS [pediatric], 2011):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15-24 kg: Atazanavir 150 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25-31 kg: Atazanavir 200 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     32-38 kg: Atazanavir 250 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;39 kg: Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     100 mg ritonavir once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Treatment-naive patients &ge;39 kg and &ge;13 years of age who are unable to tolerate ritonavir, refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiretroviral-experienced patients:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Atazanavir without ritonavir is not recommended in antiretroviral-experienced patients with prior virologic failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ritonavir-unboosted regimen: Use not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ritonavir-boosted regimen:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15 to &lt;20 kg: Atazanavir 150 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20 to &lt;40  kg: Atazanavir 200 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;40 kg: Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     100 mg ritonavir once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Alternate recommendations (DHHS [pediatric], 2011):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25-31 kg: Atazanavir 200 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     32-38 kg: Atazanavir 250 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;39 kg: Atazanavir 300 mg once daily",
"     <b>",
"      plus",
"     </b>",
"     100 mg ritonavir once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment for concomitant therapy:",
"     </b>",
"     Children (antiretroviral-experienced or antiretroviral-naive patients):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coadministration with H",
"     <sub>",
"      2",
"     </sub>",
"     antagonists, proton pump inhibitors, or tenofovir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6 to &lt;13 years: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;13 years and &lt;40 kg: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;13 years and &ge;40 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Ritonavir-unboosted regimen: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Ritonavir-boosted regimen: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2533373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F137357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Not on hemodialysis: No dosage adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-naive patients:",
"     </i>",
"     Use boosted therapy of atazanavir 300 mg with ritonavir 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Antiretroviral-experienced patients:",
"     </i>",
"     Not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F137358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atazanavir:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild-to-moderate hepatic insufficiency: Use with caution; if moderate insufficiency (Child-Pugh class B) and no prior virologic failure, reduce dose to 300 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic insufficiency (Child-Pugh class C): Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients with underlying hepatitis B or C may be at increased risk of hepatic decompensation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atazanavir/ritonavir: Use not recommended in hepatic impairment (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reyataz&reg;: 100 mg, 150 mg, 200 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F137332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food. Swallow capsules whole with water; do not open capsules.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F137330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infections in combination with at least two other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Includes data from both treatment-naive and treatment-experienced patients. Percentages listed for adults unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 21%; median onset 7 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Cholesterol increased (&ge;240 mg/dL: 6% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 14%), amylase increased (&le;14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (&ge;2.6 times ULN: 35% to 49%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased (6% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (children 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: AV block (first degree: 6%; second degree [children] 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 6%; children 7%), peripheral neuropathy (&lt;1% to 4%), insomnia (&lt;1% to 3%), depression (2%), fever (2%; children 19%), dizziness (&lt;1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased (&lt;1% to 8%), hyperglycemia (&ge;251 mg/dL: 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Lipase increased (&lt;1% to 5%), abdominal pain (4%), vomiting (3% to 4%; children 8%), diarrhea (1% to 3%; children 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (3% to 7%), hemoglobin decreased (&lt;1% to 5%), thrombocytopenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Jaundice (5% to 9%; children 13%), ALT increased (&gt;5 times ULN: 3% to 9%; 10% to 25% in patients seropositive for hepatitis B and/or C), AST increased (&gt;5 times ULN: 2% to 7%; 9% to 10% in patients seropositive for hepatitis B and/or C)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinorrhea (children 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2%, postmarketing, and/or case reports: Alopecia, arthralgia, AV block (second- and third-degree, rare), cholecystitis, cholelithiasis, cholestasis, diabetes mellitus, DRESS syndrome, edema, erythema multiforme, immune reconstitution syndrome, left bundle branch block, macropapular rash, nephrolithiasis, pancreatitis, PR prolongation, pruritus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, Stevens-Johnson syndrome, torsade de pointes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F137335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to atazanavir or any component of the formulation; concurrent therapy with alfuzosin, cisapride, ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), indinavir, irinotecan, lovastatin, midazolam (oral), pimozide, rifampin, sildenafil (when used for pulmonary artery hypertension [eg, Revatio&reg;]), simvastatin, St John&rsquo;s wort, or triazolam",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Concomitant use of quinidine or bepridil (currently not marketed in Canada)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F137319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated bilirubin: Asymptomatic elevations in bilirubin (unconjugated) occur commonly during therapy; consider alternative therapy if bilirubin is &gt;5 times ULN. Evaluate alternative etiologies if transaminase elevations also occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Protease inhibitors have been associated with a variety of hypersensitivity events (some severe), including rash, anaphylaxis (rare), angioedema, bronchospasm, erythema multiforme, Stevens-Johnson syndrome (rare), and/or toxic skin eruptions (including DRESS [drug rash, eosinophilia and systemic symptoms] syndrome). It is generally recommended to discontinue treatment if severe rash or moderate symptoms accompanied by other systemic symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrolithiasis: Cases have been reported in postmarketing surveillance; temporary or permanent discontinuation of therapy should be considered if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormalities: May prolong PR interval, use with caution in patients with pre-existing conduction abnormalities or with medications which prolong AV conduction (dosage adjustment required with some agents); rare cases of second-degree AV block have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Protease inhibitors may cause hepatitis and/or exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying hepatic disease, such as hepatitis B or C or cirrhosis; monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of atazanavir with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Do not use in children &lt;3 months of age due to potential for kernicterus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C8 (weak), CYP2C9 (weak), CYP3A4 (strong), UGT1A1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Atazanavir may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of Atazanavir.  Management: Concurrent use of atazanavir (without ritonavir) and bosentan is not recommended.  Bosentan dose adjustments are required when used together with atazanavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: Atazanavir may increase the serum concentration of Buprenorphine. Buprenorphine may decrease the serum concentration of Atazanavir.  Management: Avoid this combination in patients un-boosted atazanavir due to possible decreased atazanavir concentrations.  This combination is not contraindicated in patients also receiving ritonavir, but monitoring for buprenorphine toxicity is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Atazanavir may increase the serum concentration of Contraceptives (Progestins).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Atazanavir may decrease the serum concentration of Didanosine. Reported with enteric coated didanosine capsules. Didanosine may decrease the serum concentration of Atazanavir. Specifically, the buffered formulation of didanosine may decrease atazanavir absorption.  Management: To avoid therapeutic failure of atazanavir the drug should be administered 2 hours before or 1 hour after didanosine.  This recommendation applies to both buffered didanosine products and enteric coated didanosine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Atazanavir. Management: When used with efavirenz, the atazanavir regimen should be atazanavir 400 mg/ritonavir 100 mg daily for treatment-naive patients; treatment-experienced patients should not use atazanavir together with efavirenz.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: Atazanavir may increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Atazanavir. Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Atazanavir may enhance the adverse/toxic effect of Indinavir. Indinavir may enhance the adverse/toxic effect of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Atazanavir may increase the serum concentration of Irinotecan. The metabolism (via glucuronidation) of the active SN-38 metabolite may be primarily impacted by this interaction.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minocycline: May decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: Atazanavir may increase the serum concentration of Nevirapine. Nevirapine may decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pitavastatin: Atazanavir may increase the serum concentration of Pitavastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Atazanavir. Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Atazanavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Atazanavir may increase the serum concentration of Rifabutin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Atazanavir may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Atazanavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Atazanavir may increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir.  Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Atazanavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Atazanavir may decrease the serum concentration of Voriconazole. Atazanavir may increase the serum concentration of Voriconazole. Voriconazole may decrease the serum concentration of Atazanavir.  Management: Voriconazole should not be used in a patient who is being treated with ritonavir-boosted atazanavir unless the benefits of the combination outweigh the potential risks.  Extra monitoring for both loss of effectivness and toxicity is warranted.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Atazanavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F137349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Bioavailability of atazanavir increased when taken with food. Management: Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort decreases serum concentrations of protease inhibitors and may lead to treatment failures. Garlic may decrease the serum concentration of protease inhibitors. Management: Concurrent use of St John's wort is contraindicated. Use of garlic supplements while taking protease inhibitors is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Atazanavir crosses the placenta with cord blood concentrations reported as 13% to 21% of maternal serum concentrations at delivery. An increased risk of teratogenic effects has not been observed based on information collected by the antiretroviral pregnancy registry. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk. Hyperbilirubinemia or hypoglycemia may occur in neonates following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to atazanavir, although data are conflicting.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The DHHS Perinatal HIV Guidelines recommend atazanavir as a preferred PI when combined with low-dose ritonavir boosting. Pharmacokinetic studies suggest that standard dosing during pregnancy may provide decreased plasma concentrations and some experts recommend increased doses during the second and third trimesters. However,  the manufacturer notes that dose adjustment is not required unless using concomitant H",
"     <sub>",
"      2",
"     </sub>",
"     -receptor blockers or tenofovir or for ARV-naive pregnant women taking efavirenz. May give as once-daily dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health Although earlier initiation may be more effective in reducing the perinatal transmission of HIV), also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F137340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F137341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be taken with food; enhances absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F137338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Reyataz Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $1318.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $1318.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $1318.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $1306.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F137327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Viral load, CD4, serum glucose; liver function tests, bilirubin, drug levels (with certain concomitant medications), ECG monitoring in patients with prolonged PR interval or with concurrent AV nodal blocking drugs",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F137342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Atazor (IN);",
"     </li>",
"     <li>",
"      Reyataz (AR, AT, AU, BE, BG, CH, CL, CN, CO, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NL, NO, NZ, PE, PL, PT, RU, SE, SG, SK, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F137318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F137334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; enhanced with food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via multiple pathways including CYP3A4; forms two metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Unboosted therapy: 7-8 hours; Boosted therapy (with ritonavir): 9-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (79%, 20% of total dose as unchanged drug); urine (13%, 7% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JM, Andrade-Villanueva J, Echevarria J, et al, &ldquo;Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study,&rdquo;",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2010, 53(3):323-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/31/506/abstract-text/20032785/pubmed\" id=\"20032785\" target=\"_blank\">",
"        20032785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9353 Version 51.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-FC54B750F8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_506=[""].join("\n");
var outline_f0_31_506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855135\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137372\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137356\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F554147\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2533373\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137357\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137358\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137329\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137315\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137332\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137330\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137370\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137335\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137319\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137366\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137349\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137325\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137339\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137361\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137340\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137341\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137338\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137327\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137342\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137318\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137334\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/51/9013?source=related_link\">",
"      Atazanavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/7/7290?source=related_link\">",
"      Atazanavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_31_507="Poisons causing nystagmus";
var content_f0_31_507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common poisonings that can cause nystagmus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Anticonvulsants: carbamazepine, phenytoin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barbiturates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextromethorphan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phencyclidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scorpion sting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_507=[""].join("\n");
var outline_f0_31_507=null;
var title_f0_31_508="Causes of hemolytic anemia in children";
var content_f0_31_508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of hemolytic anemia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrinsic red blood cell defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enzyme deficiencies (eg, G6PD or pyruvate kinase deficiencies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobinopathies (eg, sickle cell disease, thalassemias, unstable hemoglobins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Membrane defects (eg, hereditary spherocytosis, elliptocytosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extrinsic red blood cell defects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Auto-immune hemolytic anemia (AIHA)",
"        <ul>",
"         <li>",
"          Warm-reactive",
"         </li>",
"         <li>",
"          Cold-reactive (paroxysmal cold hemoglobinuria or cold agglutinin disease)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver disease (eg, cirrhosis, hypersplenism, acquired disorders of the red cell membrane [see topic review, \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersplenism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxidant agents (eg, dapsone, nitrites, aniline dyes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microangiopathies",
"        <ul>",
"         <li>",
"          Hemolytic-uremic syndrome (HUS)",
"         </li>",
"         <li>",
"          Disseminated intravascular coagulation (DIC)",
"         </li>",
"         <li>",
"          Artificial heart valves",
"         </li>",
"         <li>",
"          Kasabach-Merritt phenomena (destruction of platelets and red blood cells within a vascular tumor)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal cold hemoglobinuria (PCH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxysmal nocturnal hemoglobinuria (PNH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of anti-D immune globulin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     G6PD: glucose-6-phosphate deficiency.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Michael Recht.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_508=[""].join("\n");
var outline_f0_31_508=null;
var title_f0_31_509="Pleural effusions in HIV II";
var content_f0_31_509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pleural effusions in HIV: Differential diagnosis and diagnostic testing (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Etiology",
"      </td>",
"      <td class=\"subtitle1\">",
"       History/physical exam/lab findings",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pleural fluid characteristics",
"      </td>",
"      <td class=\"subtitle1\">",
"       Additional tests of pleural fluid",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other helpful tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kaposi sarcoma (KS) associated effusion",
"      </td>",
"      <td>",
"       <p>",
"        Skin lesions of KS",
"       </p>",
"       <p>",
"        No pleuritic pain",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Large to massive, bilateral effusion(s)",
"       </p>",
"       <p>",
"        Hemorrhagic fluid",
"       </p>",
"      </td>",
"      <td>",
"       Cytology is negative",
"      </td>",
"      <td>",
"       <p>",
"        Chest radiograph: diffuse pulmonary opacities",
"       </p>",
"       <p>",
"        Endobronchial lesions of KS",
"       </p>",
"       <p>",
"        Pleural biopsy is negative",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multicentric Castleman disease",
"      </td>",
"      <td>",
"       <p>",
"        Fever",
"       </p>",
"       <p>",
"        Cough, dyspnea in 60 percent",
"       </p>",
"       <p>",
"        Peripheral lymphadenopathy",
"       </p>",
"       <p>",
"        Anemia",
"       </p>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Chest radiograph: reticular or nodular opacities",
"       </p>",
"       <p>",
"        Chest CT: mediastinal adenopathy as disease progresses",
"       </p>",
"       <p>",
"        Lymph node biopsy",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic lymphoma",
"      </td>",
"      <td>",
"       <p>",
"        Low CD4 level",
"       </p>",
"       <p>",
"        Serum LDH high",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Large, serosanguinous exudative effusion (may have mass effect)",
"       </p>",
"       <p>",
"        Pleural LDH high",
"       </p>",
"       <p>",
"        Cytology positive (60 percent)",
"       </p>",
"      </td>",
"      <td>",
"       Flow cytometry",
"      </td>",
"      <td>",
"       Pleural biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Primary effusion lymphoma",
"      </td>",
"      <td>",
"       <p>",
"        Low CD 4 count",
"       </p>",
"       <p>",
"        Preexisting KS in 30 percent",
"       </p>",
"      </td>",
"      <td>",
"       Pleural fluid cytology usually diagnostic",
"      </td>",
"      <td>",
"       <p>",
"        LANA-1 (HHV8) +",
"       </p>",
"       <p>",
"        Lymphocytes often:",
"       </p>",
"       <p>",
"        CD45 +/CD30 +/EMA -/T cell antigen -/LMP1 usually -",
"       </p>",
"       <p>",
"        Monoclonal B cell population by Southern blot",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Chest CT: adjacent parietal pleural thickening and absent lymphadenopathy",
"       </p>",
"       <p>",
"        Pericardial effusion and ascites (common)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thromboembolism",
"      </td>",
"      <td>",
"       Risk factor(s) for thromboembolism",
"      </td>",
"      <td>",
"       Exudative, may be serous or serosanguinous",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        d-Dimer (positive)",
"       </p>",
"       <p>",
"        CT pulmonary angiogram",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypoalbuminemia",
"      </td>",
"      <td>",
"       Bilateral peripheral edema",
"      </td>",
"      <td>",
"       Transudative",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Serum albumin (low)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart failure",
"      </td>",
"      <td>",
"       <p>",
"        Chronic dyspnea",
"       </p>",
"       <p>",
"        Bilateral peripheral edema",
"       </p>",
"      </td>",
"      <td>",
"       Transudative",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Serum BNP (elevated)",
"       </p>",
"       <p>",
"        Echocardiogram",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMA: epithelial membrane antigen; LANA-1: as latency-associated nuclear antigen, a latent HHV8 gene product; LMP1: latent membrane protein 1 of Epstein Barr virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_509=[""].join("\n");
var outline_f0_31_509=null;
var title_f0_31_510="Structure of selectins";
var content_f0_31_510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Structure of selectins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 308px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The protein structure of selectins is characterized by variable numbers of short consensus repeats (related to complement regulatory proteins), an epithelial growth factor-like domain, and a C-type (calcium-dependent) lectin domain. Three selectins are known to exist: P-selectin, E-selectin, and L-selectin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_510=[""].join("\n");
var outline_f0_31_510=null;
var title_f0_31_511="Fusarium toe cellulitis";
var content_f0_31_511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusarium toe cellulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 307px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEzASkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDqlBzjjt271IEA5pVGRmlWtgFUZ69KlmuEsoDLIRwOAQOaapVELycKK5TWr9ruYgH5R0rKpPk1Zvh6XtZFTUL+S7umdiTjgdqrEEnJJz9aeiCnhN1ebOo5M96lTjBWSIAh9TUgRiO9WBCMdMGpBFhc4xj9ayaNU/6uVPLPvR5ZxySTmrYx6daikBzhetJju/6ZA+EAyeDxTW5AwcVYEIIz/FTDFg5NIL/1ciZT2JFMIYcZ4+tPKFmKhiO9IYyF5pA/61I/mPejZxn+gqVV6UrA5wK0TRLT/plZo/X+QpjIR/8AqFWjHkA5pCmQa0TMZR9SoOPUVPa3MlvIrxMUcelMdMA0wD1raEjmnTujv9A8QpdbYbsqk3YkABq6Nj6bfyrx9SwYMDgg8HNdVoPiBkUQXb5Xs57V106q2Z5dfD21idZMwGcdfpVCdwcZ5xT5ZlZdytlT0NZs82GJB7VucepBfSZVulchfsd5OMEV0lzKD1PWsC+AJOepoK1Ms8n/AOsKnjyFHOKQqAakXGKY7sfESGBya2bO4KgZORWKSBT458dDSBnVrdZj+XmpbXc7DgVz9td8gZ4rf064TAOaZNjetV+Xmr8agYP/ANaqNvMrKOauRyDpSEWlbA7/AJmnZPqfzNRK3FP3VNg1EYEnBJ59zTMmpOv86Zim7DTZzyHA/CnL1GO9IOuPYU/hVLHjA60uhruZHiC92IIUOMjmucyCata0++UFeSap4wFHc9a8+tNt2PewdFQjcnQAe9WIUDA8VUDbQSfuAcmtC2w0YK/dPSuZnW1YWOIFfm6+tEgwMDqOKsBcYOKY68tx29KRKZX2jH4VGB37ipHU428+tNUA9KTNFsHao2Qlie1TEdqTIOR04pCK7KR0HFNY8jI4qVjwPrUZGcg/hRYYzA+YflTSOhHUU8gDFIeD7UAJnP0pvA+lOJ4xUdUmQ4jXUEEVEVAANWMAgH3pjoDjAxWkWYyiQsOxHUUR/IcCpCPXrio2GTn0reLOacDZsNSMSCORvl6CrM9zkfKcgiucBOMN2ORVmG4OzbIceldVKp0Z59eh1iWbibuayrifLVJczYyO9ZcshLV0HHaxMZeaekmeaphsmrEIOetAEsr8VW8zBOKmm+7iqbcUDLcVyQeta1nfFcDOK5rfjtUkdwVYGgLHoNlqPT5q3rW7EiivNrO8+7zXSaZfHcMniglo7iGTIqwprHsrkSKOa04myKTEWAf5GkoT+hpcVLHE53HNVdWm8mwkIPJGBVscE1ieKZAtvFGTjNRUfLG7OijHmqKJhTMZHyelLGnXOSarh89DzV2BuhbmvNk7s+hp+7GwzB2nAyKuQvsQY44ximlflJxSdwFPSoaNL3L0LDbljk0FweKhQnOF5GOacxwBnn+lIloSZQTnnGKgicZIHIqaRjjjkGq44OTxjtUs0jsSkKc5qNsHtilkkVSPemg89KQ7DNvNNbgZqRhjmo2wRzQPQY1MbJOMVLikK4OaYhhAxnvUbLlvapgmTTwmOtCJbKqpjOO3NSYyBUpA9KYOKtGUtSJlzxUD4GQOtWnPFQuMnNaRZlJFYZBIPOaQ4xjr6e1SOOaj71vF9DnlEWaPzIsg/MB0rHlbDYrXyQeDUd5aCZfMiHzjqK6qc+jOCvR6ozUq7B0qnGpBwe1X4BxWxxjZulVHGM1fkFU5V60MaKL8GotxzUso561CRz1qblF22lKkc1uafdfMOa5lW2+9XrKbDCmmgseiaZcZ2810trJlRXAaXc9Oa6/TrjKjnNBDR0SEYo3VFA2Rmn496UiYmCPvc1y/izc88Sj0rqCvWua8Rxs12eCRjisa/wAB3YW3tLmHFCV68+9Wo1bco7Uqho4ghPBPSpoE3RBo/nG4qR6H/Oa809nmJWbjjnHamqPw96AFzlWyM4+tOQjkHt+tDKiyRDtTimFsjk80hGRjPU5+lNkPQdMVJqtR7ONnp2qEklgT06UMw65oV96Yx0pFoVOtOP8As1EflI9DTgeceoosUP8AvdTgVGwHI64pw4X6Ggj/ABosSR4xR1H0qQjIBxTGGDRYA6DIpQ3NNx2FKo+WhEsdjJprjApQcmlxnNURYhYYqByKtEZGKhZOtUmQ0VjTDx2qV8jjFRk5rSLMZojPSpI2KkY5qJjg0c461vE55xFu7UN+9jHPcCmRD5AR1qxA+07T93vTLhfKYkDCmumnPozz8RS5XcgmbANZ88tTXUnXms+Vs1pJmKQx35NM60pGRTATnFZlWHk4FSQMQwOajPShODnNMLHRaZcEMvNdlpVyDtGa86s5tjCun0a7+YZNWgaPSLRwVGD7VY8ysXTJ/MVee9aO+lIzsUD7fWsPxLGzxx+Xwx4JrcAyaoa+udMcDsetZ1NYs2ou00cxZwtFOVmfJTp6GruoxPJNFLbHaJE+cIOMjvVGxuQ8bLt3/MQTV+3uRtVdqyLnaI+4NcCsz1m2ijGxSNopBh0P5CpVJ2A9al1GKFVjuYDln4dRzgc9fyqBRg4J4I4rOSsb058w7cSew7U2Q5HvS7QAeeajI3EZqbHRED9aVcBOOtJtGM9MHFNIILD15FOxaJFJY9ulC5JHPvTVXp708AYQUrFEgXGacBnvjtSJxg4z7U/b8jcEDrVWJY1VOCDz+NNC5z2IqYrjAB4xSYJIwvUetFhXIGH6Umcr0p+09aGHFJh0IwMYNL3pwIwKaTzmkQNdcGoyKlPPWmMMd800yGivIuOlQMuKsuMjpUTLxVoiSKrdaYTUsi1D+FbxZzziPU/N1qyR5kZVuvaqy4/Gpom5HrW0X1OaUb6Mx7nOSDwR1qjn5sGtnVYgspcdGrHZcNW17nC1Z2HEcVXb71WAcioiMvyKQ1sLximE4qVhgcVA5oBEiyYrZ0u62svNc/k9KtWcuxxVJoqx6loVzu281v8AmiuD8PXfKDNdb54/vVTRm0W16/hVXVIxLYTL3AyKtgf4UuwMrqRkEYxUWuhJ2dzzFb97aaS2CAo7hxjjn61vaa87T5iXzGXkDHK1TFjFJ4gW3lChQ2ct7V1ltGlveSTQzxZkXGCmdp9QM+ma86Kadj1p1E43KVvp8xhk8zCxyfIuPUnrWPIuwsrcuh29a7S8dVghRpgxxzXJ6kgW+lG3aCcipnuGHndlY8Y9TTO+aaWxn69abuyQM1B6UdibduzgexpvtSR9wR3605wASR1FOzLQg7elKVwRjsaOgPtUqhctk9RQkMkQZ3HpkcVPFhtuehGKjQbmj9CKnjAVFJ9aozbHGNTtz24pm0KVxnjirC4xwOhokTg4GSDmi1yLlFlxnjvULjB4q5MhyOwIqnIC2Rjp70mi07kLHFIPXNOMZ65ppz2qR2FyOnegjIpADnrQTjvSBoay1A+asdRTHTiqTM2ik4qErzVqReagcYrSLMJoiAOakU4b0pueelKvXjrXRFnLJE9zEJrYkckDNYckfAyOa6K1w0ZB+lYtwmyWQEd62gzhrxs7me4x0pi9akl61Epw1UZJj3+7VWT8quE5XFVJepoLREMZ60+NtrDFREgUuQD1pMtI6XRbkq6jNdZ9s/2q89sJdjjBrc+2n/JquYmSPUo/vU9RySD+FMUYP6VMoznHWmjE4rU2EWqHIG4v1+tSwXRF18+/apI44yBTPFMJj1ZXI/duOD6mqW9lYLKd27gdsV59S8ZM9KFpQSOsS4gjiEjwq6E4WTPIPoa53UZGkuZXfjcePpU0LyKNrMoQHAAHHTr9aoyMzRFnIOCQKy3NKELSKznP4UkZBcccUF/xHpTVO0+xpJHqLYtx7ew+9xTpMZHbPWoFyqj8xUoGQc9TyKoY4AENk84p4wHHHBFIADt78Yq2YhgeuKBXGxDCIfepVPJHYGowjIig9jUqgAyjOe/SmSzQhhyvPfnirCW4LE/mDSWLB44ieARjNX4IS7yFVOFNWkcspWepiXMLKg3dj2qhNGFkPHaulurUHzMA9KyruMCVCBkMMVLRpTncxiuOQeDTGXBq3PHhW28YNVXWs2b3GEZAxTMHNPGRg+9NJJY1IXAdaDzSDrQeKBMhlXPNVmHOKumqj8ORVxuZSRXcUKSCKe3NRZw1dEWctRFy1IJNUNXXbdMQODVq2fDcVBrX/LNvatqbOOurq5iy81DjmpmOaib61qciJB0qtKOTUwPFQynFBois3WkyKV+tRFuelI0RZgkIIJ4xWn5nvWIG561Y88/5NK5Mke+jr+P+FPxjmmZ5/H/Cpl61a2OcxvFlqsunK+MmM5BrknOSgX5io9K77VYTLp0ygZbGa8/tVLTEtu5OABXJiY66HZhpaGna3PkQFNqNkHJPOKzpXPlqOxzRMXWVs4AB7VWllBzjk1z2PQoRvqIx+bjipUIJx7VXjORzUq8DHeg9BbFiI5YAngcVMjZKEdBx9aqIGBBA6VNFgp6EN0piZZjBSbB6Zq8fu4J+bOKoQyBid3GT19KmDDEmW6EMKCCZSzK0Wfm7U5GPmMCMHFQswEjPg8nOfSpYj++j5/hOTQDNSx3bFU/d610VjjdckE7cA4rmrVsGAHowwCK3rBmxORgKeKtM46qJ7klptqEYK88VjajCUhBK8qetbRbMikKOUzx2qpe5kRgy8Fc0PUzhJpnMXnyyOCMBsEVTfrx3Falwu6NHbk9KzJQd7j0rNo7oO6K5HNQuPmxUx42k9zUL5357VDLsJGMk05uKE4/OlPPPrUiZExzVd/vGrDDBI9OahcZ7VpEzkQNyaiYc1ORTGWtUzCSEg4bNN1gf6MGz0NKvFLqPzWDY6it4NHHVjozn2OKhY5p7c8GmlcVucVkAJqCYnPSrCdaiuBwaRSKhNRv2pz9ajfgA1LL6AW2mjd71E7DFM30hyPpLHzke/wDhUqeneowOT9alQdTW0TlH8HArl/EFmunx/abZBgtyCOnvXUcDn0rmPFl8pP2Nc/LhnJHFRUs43ZdBPnsjk5GbLu5G5j2qsnJznmnXcoLYUYXPFQqeetefPyPoaUbJFpevTmnoctVZJOvr606OT5mAqL2OlItFyOO1SoAAG55NVkfPWplcsDk89qpNMLMsDA5zxU45QDqxPH0quTz1+VuvsakhPzLjJPamS0WHcujMRjPH0qWMsJeVyu3FNfEcThgflOfrVlGRtrEEAimQ9CzasubdP7uTV23nfy2UMQOfxrMcGONLmPJUZBq7bfMkWCCG5pmM0jYs0d/KIkxhefpUl5xErEEgjbVFJ1TdtBzjB9qmvJkaNRExwByDVHNKOtzKv48CVVGNtZMqkEluTitu6QNDKwOCSOprJuFxIw64GKzZ103oUGwFXNRDJyMVLIpBwegqPPHFZs2GdKUdAPenBSeSKToelSSyOQZY1Ew9qn61G4NUnYhlcikxTxn9cUYrRMzaRERTJhm3kXHapjUcgzHIR/drWDOerFWZzcgAf0prHmo7h/3pOaTcCOtdd9DzJLUfuxUMrZBzSlh61BK/WmNWIGOTTGOBQTmmMazZfQjYkmmfhUicsKfsoFJn0iOv4n+lSJ3poTjr/nilXritlocw8nA964HxhMW1llU/Kij8c13y8HrXnPisMutXIPP3SOO1ZVfhsdODSdQwZm5yTUTSleADnrT5yQ+VwSPWoXY/eJz6iuCZ9BTtYnjc7ck0+OddzZPPpVZWI5HI9KmgCnkgA1i7m6sWUIc5B4zVoFQRjqKpFliOVB5qVXJANOMug7F6CVuV4x1wRVoAMgZfvL15rMhYlsscGrUTbSSDkdxWiZDRpwSM/BwSRgg0sMjQOEYjHp1qpBPtfpwauB45FPG1h+Oasyku5fhkM1nNHwAegFOsJD5Cq0Z3RnjHrUFn+6lRjjHvSxLJHcO0ZzlsgDvQYtXLbXJMhAwc9e2KkWfzFPIBzjmqk+HkDkBHbqKjBVjjPzDilcXKmWbn5yPm4LDiqNwSXkI6dBzU6yEOemBUMoAVfzJqWXFWKEgILBhzTUQYJNWHySxI69Kao+YZHvUljGAGOMVC45zjrU78tgflTXA28kZpAQD39elNcfMPT+VSd8446UhBIxTIZV+o75pDznAqZ1PJx7D6UwIwH1q4mciLsaQ8wy/7pp7jaB6mkUfJIP8AZNbxsc9R6HBzS5kP1NNEtVrhsSuBx8xpIznrWsJdziqRLPmEmmOTQopHrUysMzxTGOaUmlVe9SyhYVwam2U1BipM0hSR9HYO3p0NRjg1Pg85PFQH7xrZ7HMPBz144rjPHFuFuEuM43rs6d67E8jFY3iy2NxpblFyyHfU1FeJtQly1Lnm0oIY8fNVbPXJGfpVyUAgA5yeuKoTEq2GHyjvXnzR9DRd0PHHIHFWoQH69u1VEI2+xqzB3OTWVjoRbIBUjHFMjBGcUeYCdvfFIM7+eBUNFInRiwwQNw5qWMkEZGM+lVJAM7lJyO1TxOzFSOlUmVYvJJhsjr0q/AUIBIGe9ZiYOe9WrZmXBA+ua1RlJGiSUAYMDHnkVYKDzEdJCARxioI4FcqyuF3cde9WzOkVtJCcFhzkimYPcrCVlYiQjIPJPent8w3EY9MCoMiZVcH5k7kUgYt0LEk44pMLD9xzt79aVxvbaD1/Soj8jAP8vPc1M52EgDAxwfWkxXsQlS2Rn7tNIIjyBtA9e9SthcAdeuaYys4AA3enpWY7sg64ODSSIM/MDVnyismPvEDoOlRuBkknn0osK5W4AwoNIeMgdKl70wjApgRMKaxwAP1qRulRMOMDpVpmciKTkilgG52HsaR8dRzin2w+fJ79q2gc8zzDUV2Xsy56OaSJuKn8Sx+Rq06jjLZxVKB6uOjMJq6NAH5agdsmnbhsquzYYmuh7HMiQHPFSKOKrx8nNTFqkB7NgfjRv9qgZs8e9LvpDkfT4GRUDrhqtKOP8+1V5uvStzkIx1NR3AEiMjD5WGDS7vao3bg0Be2p5tqVt9mvJoSMYbIrImUnIIyDXZ+LYAWjmx8xGCfWuRuEKlj2NcVWNme5hanNFFKJfKJUnjqKmibnrUUrDbkjkUqAMy+n1rkejPSjtqaHBxu/MU9hgjnOagjmVQVY47c1My4+nbmpZaFY+X83bvU8LYHHI6iq7bXiINS22F+XGe9CL6F6MgYI6GrSyYUZH0rOVhggnHer9pCJY/vFj27VomZMuWjQy8SyFWzkVfZpHyuUOBwSOtVLfTjLhRtDejnFXngaAbCCjr0HqapHPJq5VEbKWaTK4H3V70xD0I34+lWHllL4kI99wqCQ5PTgelDEmPVEZwXHy5/iNHnI2UYlgvTApnlnIYIAPc1GSUk+Ujb7UgHF/RTkepp8eSwdu38K9KiKMzb1DH69KlQ7SMkDPHFQDLTslxnavltjoD1qi6gE5xViNCGZlIGB1NRjExYjAA6+9BEVZlRuDxTTT5OOgqMjpQUNYcVE3Q/rUvSmNTW5DK0x+Xd2HAFJFlSQevXPpSyDqCMt7VFgqxUnnrXRAwmjjfHcGy7S47OCOlczG+DXfeMLc3Ojs4GWiOfwrzhXq7WZzy2NJJCaU1VhbPNTbq2ucxOhAFNd803dxULtyaTYyQNk0/dVZTk1LmkOR9Wp0/z6CophkGpkGB/n0FMl6YxW6OJlE9xVaU4zU8hxntVC5kwDnpVDM7Wx5lk3OStcVdp84J5FdhcygqysflPWuavVUsAOoHIrnrrQ9DAzadjCuU3l0Ujg9fao7QDawPPNT3saxPu6ZHNVYbpYXwU3qfQZwa86ejPcp6o0VVWAyAccCpQ3ZgKpx3LN8zoI1JwOKmTDYOcsahtGqRNuAPHFSMGOCvSogACD19qniJGTtOO1G5RJCgI3E81cjZGZB/ED64qtENq4I68mpoWTf+7Qkd81UURI3LaSRlCK7be59PpV25V5ERQS2eQ3Uis2yLJsIRiQPTFX3uZ4YTtAAPXjmtUzlktSGX5ecFm755pGuMjBUIMVBLMSS2SCe2KhkYFgOSSOlDZaWmpK1yqAEbmJ7VKrIxUgqpPJB5qpPKRKqEKqntTmU4UxpkHvUticS7PJEYv3e4nv6Co4mLKoWMAg8N602GMrv549PWnYd1GPlA5xSJskKG3Flk9OvaolARiACQePapQdoKKudw5JpyoVxuINIkiKAjGKgkTB+lXHGV9DVeQDB+bJoEVGOKYx6Ad6fIecdKgeQNlRnPSmFiN+CxU4A7+tQEnHIGT3q22AgyOlVzuAO4DJ6cVvFmExJIvPtJYTjDqRXj90hiupYyMFWIxXsqkkowXGOteZ+M7P7Lr8wAwr/MK2WpyTMuE4WpQarpxTi/FWYj2eoyxJphagHnNJjRNHxU+agTqBUm72oQ5K59Zp0/H+gpsgzSxkEH/PYUrZwTjNbxOFmbdDqaxLxtp68Vv3akKa5rUuuKoa2Mi6lyxB6Vm3zbgshAy2QcVfnXc2B1zVO5QCJvUMRUVrcp1YR2qGJcFWPzckdKqCILu2gcnJq3cBQ7cY7ZNVY9xUEEYNeTU1Z9DR2FVwm4FuD7ZxVyLJRcA4PrVfYoZSTzn0q4rhiBWdjoHYAOD19qsR8yGMHIFQgKoO44ojk2k+Xk9+apaC3NWBPKBwASfWpbaMuSwHI9KowzkD5zz6Yq3HcKFwM89hWqkjKUWa0dy6kbgTj0qNrlndkPfnJ7VVDOAArEZ7damj8lVLPuLj1pqxnyoQNk5UdfWpBsOC2A4PP0qOJmY/KOvFKh2ySLjccU7AKxVpMlBj1NWA+FUR4wPWqhZQFY5+lSWw80udwAqWgktC4ih9oQ5bvTgvzEAAk9vSo4xtcEfw0K+0kZOSalIxY6QNnDdabwDjvSk5bjJHrTW9hzSYtRjnA2iq8uFIHfNTPGdx38cdKgZNpO37vvQNFdsZ56noKiIIbaoG49amMZ3ZzzSGFVIO4+5oRTEEeD8xye1Quo3Z655xVpee2QO5qKVOB7VvE55ECgknt7VxnxIhHm2lwB1BUmu3RBuBNc18Qod2grJj7j/41vE5aiPOC2BTC+aYW681GWxVHOS5qRe1Vg3NTI1JjRaQ8g07d7VEpozQmV0PrtAR17//AFqcRxikAOBz/nApWOK3RwMpXn3SCa5fUeZDXR37cNzXM3TZkPFUPoUVTc4wOc8VnX+GVyn945+tbQ/dxtIccc1z11ycq/zZJP41nXdkdmEjedzDv5AjbeMtTYsbF2gcUlyfOnYuBvHQDpinqCsfSvKl8R9BTVkKzruyQc9KkQHIOce1Rs5KjaoxUg+ULk/pUs3Ww8NgHkE+9IszB85wR0pWTdggYpD97sPrQUrEoZnfexw1W8sMFTx3xVKHl84z2q3ESqsQx3f3faqRMkaNvJsQjHUdxV6EqwXauARyfSq9k6uq+awUD1rVISeBxaQOw/vgcVpE5pysyk4kjG8giM8Zx1p4lUENICq/rTpbaQJGXkHPZTnH1ouHDuVAXGPXmqEVJmYSbVBB759KktlCk8EnNMYGR0d8ndxkCrcLk8AAAcEkVL3HLYkikCxOCuT605PnizuGR2700hWjJUYPXI4pIgyHLcntxQZWHqrAZRuD1puNp4Jz71IrZyxU80qkdD0qGQQOWc/P1FRsrYyRmrRCknvxTQAOKAKqxKuWxz35phG5fkXPuasyAjjGaYQwXqoFNBcgxuHzHkdhUUoyOvFTZXP3ufaopQSe1aRZlIr8jHHSs3xZCLjw/dqVBwAetahIAwfWoNYiEuj3qkZDRniuiJy1DwyVsMQMcEjrUZamynDEEcjim5zVMwRMpyanQ1WTrVhKBlhDzTs0xadSRS2PsADHfOef0FMlPy1IqhU4GB0qC4+5W6PPZkai/Brnpm+fJra1M4BrAlOSQe9Wh9CnrE7CBI4zgvyT7Vi3EnDdORVu/n8xjt6gbayblztOMBgOOa4687ux7GDpWRXlC9h+NMZiFwDkYqPzcptYgN6ZpdwZO2R71wt6nrxWg5Jjt+Uc+mamzK5BC9KqIyqc9/SnrdlXyvRuMVm2apFqS5YHDDaKjaUNznIqAz8nJBPSnoRg+lJSvoVaxYik+UgNgVZjBUAktk8cd6pRsBnp0qzC20gsxP07VoiXqbVqVJEfkAsv8XXNdJYTyhFiZ9iEZ2J61zNiQX2glifTrXY6JbLLOheQwoRgg9a3gcldqK1MmZJ34wiop7dTR5YTDBRu9etaWoW+yZyWG1W2jj5j+FZspbzSobbgYPGab3JjLQiiR9soJCgcqKlt8tgKOSMHvTGZ0nVmKsF9qeH2SMyH5H5yPWpZTuSCPqrH5FHI9aQEkDJ4HA+lNDA5ycj+dI2CoyMc9aTZmyzFjaeufeiRB1HP0NQGckYUZA61Kr7hhRgVJmxrDp2HpTygGMUmctyOlJJkg5/Kgm4yRgW47Hmo5iCuQQB64pX5A7Y6CmZB+8PwoGQMoxkYphAOcmnzZbOQAPQVDjH3Rwa0iSxjkg4pWXfBIOxUjH4Ujcn1NOj7gcjBreL0MJo8O1mzMU74HRjWVXe+ILLc0hC8ZJribyHypOlUnc55xaY2OrKVWjPPSrUdU9iSdR0p1MB6fWjNCGtj7Ezlc4xUE4ylSg/L1z/+oUyQZU1sjgZz2qA7Sa52dsA8ciup1VcRtXI3bcMAeatbFLUxrkHnoOOeKx7k5fGcrWpezESlSGG4cccVz9/dpFOq4JLcEDt715laXvH0OGVkhlypEZ2D5h096r214u75jhuhHvVtnDoSBxXLeIQ9vN5iEqh4yPWudq70O5S0OrUgt0FYut6ilnNHHkjvn0qzo90xtoDMpy6g5rnfGayXF9iMH5Bg7f51cIKTszKrWcIc0TT0zUreaYM864z3OK2P7QgcZWVBjvuFc74XsbdlkNzEjOpA3tyfpXTNYQMg2W6hfdRUzpqN7F0asqiu9CFLmN33eerf8CFaltJE7geagxz98VQW0t1G3y4/ptFXrfSrGTkqu7P3QKiKN25WN6xms450aR1ZD1CnJrsdHmS6CJAjmT+By3AFefx6NpyqrIg3DqAxrqvDelWvmKUs5jubblpiFrogcldO1zpb/TYLGE3n2sy3LkKy9hWJd7AWAbcAcAdTmrlxp0ltEVJkdQx+QMW21HDbSxM7FFDFeM9verZz0/dW9zLkj+YF8jj7vrTgrfZ96n7p6YqZT8zA8v6mnYXY6hhxzWcmbNkUGG564/nSSuy/M3IxU3YOq/KRzUUw3AD+HHTrUkdQVBsU9m5xT02ABQMH1qHJQDceO1SovRmOCeKQpKxaDBgAAOB1pGwV9TUSj5sEcdjmlfCDB4yaDIicetRZIzU4xzwTVZxjJJP0pjuRygZB6mgjjLcH0p+Rs+ZaiJwflORVxJkRFNxP86dGMKQegBp/8JqMtiNzjBxW8TCRyGoQiQyDHc1xOt2m1idtd9KM5J7muf1m13AkfyqYStIVSN4nBrlWwatIeKZexmOb2pI35rfdHMWV6inUyM8in0IfQ+v4gojAQ8df0pZOFxTgMKMnOBj8qjlb5TWyOBmLrDgRsPauPuCCzV0utNkEVzbjcxHfFWiomRqAOzKkBsY5rnZbQbCzAFvUGulvkJjPqRjpWEFnB2yIrc4UV5Vb4mfR4Z6JnPXEd4smYzsX0J4NQXqXl3BIksKrsUyM+eqjrW/qClJUWYIvPJzwKx9W1A2r+VC5YFCkhHI2n/6+Kxi7M6JpuLaIJtWSERKsY2KMA4NV9T1hZDEyhgr5Dcda6OOxa4tMSpCxIBL47Vx2tQiGVUwDtbI2ngirjpLUiUVKDsX9N1e2s4RiNi7ZLOFzXQ2usxXATgktwOKz/DscMlqN6qM9sV0UVghT5FXHt1pN6l042SuVWiaRiUGfocVZghZGHLZPvTvJEfBXB+tSBBlTgD0zWVrs609Dc01AVX5VjYDA5zk16D4Xja2g8+R4JoW+/GWAb8K8806MQlZZBlf7wOQK2bCaCOVZ1uFV0O4HqPyropySOLE0+daHod0W1GMWkBht1OX38Ege9czfKkCuI3aaQnBIHHHvUyTnM2oteWsi4HAO0HPpWczz3COqx/KzZXnAzWkpHHSp2e5STd1VNxJ5PYU48PtRVY4INSmNljK+cNiHLqhBH0pDD5pSRsIhPAHpWUjoXmVklUBlwWY+nan4UxEEneOgxUQj8uR/LVsd29qnEiyYVAQo6tWdwfcpxIpJLFs9wam2gjOSewFOeNUPH3epOetGfbFUKWo9s7VOMEdBQWJXnGR1pjuM/KcnHWoGAByM5J5oIaLG9jyxAFRTMCRgZ980E7SNxzmoJSN2R+Apk2Elz/CSe1AUheevpUmTt7Zx+VBPHFaRJkRtgKarTnETD+Iip5OBVC5Y859K1iYvUyHQgEHrWfqEWYzkc1vyRF0VgOcc1XuLbzIztHOKHHW6HfueW61Dsc8d6yomrqvEluY5G3DBrkvuuR71pE5ZqzL0R+YVNioIOgqxTQrpLU+we1Vrk4Q1ZzwOP84FVbr7prdHA9TmdYYkkZrJtk3SDIya0tWbEhqpZDLgkcA81oijE1FdrSKD0PesaQSMNy7C2ep9K6LxDEIbohmGJBlQK5i806Tl0uHjY9cHtXlYjSWp7uFleCKOtwQyE73MucERg4U8VzlzZS3GoRwRrtDjkdeK627hYwYRAQB97oTRp1kIpjdElpGHIPauNS1PVi1GNy1ptl5FmLdxkKMDNcx4l8O3AuWms0zAew7V2pEhfA4YcnIp1yu+BkKkHGcg1q5pozgrP1OC0uxuYpGhbMbpz6gj2rpbQ3USYGHHrVooBsG35lHpUyoVUeXxuHI96yvqbvVWKTzSP/rIXz7DNVxet5vlxxOzAkMCPu1qSpI0bBcq2Oo4NZ9oJbR2BSRnYks570X1LijV0u6mReVGw/wHvV8tEJiJLZnOMhU7VlW1xPOwzCpIGFB4NXGu5ky8jSx7gVRk7Gq5jOUeh1+k6hZ/ZIvtGmO0TADBIVRW/LodpdLLcpI6RBN2NuV+gP8AWsPQ3sEtLeWGaJ3VR5q3XLZ77fWtm5OnvGgtJ7nIH3WY4JPoK6o7Hk1rqdkY0k1uq7YlgTaMfKMM31pu0P5TrywOcdhVpLdEm3R2qpg8vMMc0y6z8gmkKqDygXBJ+napkkVzW2KUwxMxJyucsV6fSm71JCxqVT371LcMCgZFIA/hqqCScjgms3YtaoRxHggnPPeo3G1lwM5GAKJ0CKd3J9qiUswIkOAPu4oGkrbjid3GQvPSlJCQknn3BpnHmB3HQYHvQzDBGNq+ppkgGwpHAx096qTE89R9KnLcqOp7U5xvIJ+97UwWgyAgKBg9Op71IeeF6dzTSAOpy9NlcKoVOprSJnIhkfknPAqnIvmFs1eZABhupFRxxblZh0rRMzsMjULtwOMYoaMc7R1qcJgdOKU8DjrmqTM2cx4q0Y3No8kSgsBzXkd7G0NwVYYOea+hAocbSOD1ry/4i6CbWU3UCfuzycCriY1E2cjbHPFWPxqjasOOauZp2MZH2N2H+fSqt10P0oorZHIcjqp/fGorLqv1ooqkD2KvihQZ1JAztrnB87YbkUUVxV0e1gHshZFHmAY4AzirSxoYx8ooork5Vc9tpWLtuoaJSwyTzTZVHmAY4oop2RKir7EMyKH4AqtqKgQSEDBHTFFFKyLSRHbkmxViSWxjNLCi7d2OfWiimkjSyNW1giE8LBFyUb+VbNtYWr31mHhVlEStg8jOaKKpxXY56+kG0ei6Fo2mtYCRrK3Mis21igyKyQiiSZgq5UnHHSiit0lY8Fyd3qJYj7dqT/a/3u1CQG6DHTism9PmSxM+CxViTjrzRRUNK4Rk77mVOeMVXYnGO1FFQ0jrhJ33Kykl8HpUcpOAc0UUJI6U3YLcB2+bnjNSTorYyO9FFOyIk3YHUBFwBUZG1Tt4ooosjncn3Gwn93nvmpABkcUUVaSMm2NIBRs1LCo8vGKKKdiG2IwwpxVdwMsaKKuK1Iux0XSsvxXEkuhTeYob5e9FFaImTdjwwDbcMBwAasZNFFWZSZ//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fusarium toe cellulitis developing at the site of onychomycosis after cytotoxic chemotherapy in a 45-year-old woman with lymphoma who underwent allogeneic hematopoietic cell transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999. Copyright &copy; 1997 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_31_511=[""].join("\n");
var outline_f0_31_511=null;
